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Abstract 
Objective: Tobacco control is a global health priority. Despite global progress in reducing 
tobacco use, country disparities in tobacco control persist. To track progress in tobacco 
control efforts, this study aimed to provide an up-to-date, comprehensive and consistent 
assessment of tobacco use trends and projections and of achievement of WHO 30% relative 
tobacco use reduction targets for as many countries as feasible. 
Methods: A Bayesian hierarchical modeling approach was developed using tobacco use 
prevalence data from the WHO Comprehensive Information Systems for Tobacco Control. 
Trends for current tobacco smoking, daily tobacco smoking, current cigarette smoking, and 
daily cigarette smoking were assessed from 1990 to 2010, baseline projections were made to 
2025 and probabilities for decreasing trends, increasing trends, and achievement of tobacco 
use reduction targets were obtained from posterior distributions. 
Results: During 2000–2010, tobacco smoking prevalence fell in 125 countries (72%) for men 
and in 155 countries (87%) for women. Even if such global declines continue, only 37 
  
 iii 
countries (21%) are on track to achieve targets for men and 88 (49%) for women. These 
translate to more than one billion current tobacco smokers in 2025. If such trends continue, 
country disparities would persist and rapid increases are predicted in African and Eastern 
Mediterranean developing settings. 
 
Conclusion: Globally, smoking prevalence trends are decreasing but tobacco use reduction 
targets remain unreachable for many countries, especially developing ones. If immediate, 
effective and sustained action is undertaken, desirable trajectories may be attained and 
maintained towards global convergence in tobacco use elimination. 
 
Keywords: tobacco control, smoking prevalence, tobacco use trends, tobacco use projections, 
tobacco use targets, Bayesian hierarchical models 
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1. INTRODUCTION 
Tobacco use is a global public health problem. Smoking kills six million people worldwide 
every year [1], accounting for one death every six seconds, and one of every two smokers die 
from their habit [2]. Although progress has been made worldwide in reducing tobacco use, 
disparities in tobacco control and tobacco use measurement persist and continued vigilance is 
required to eliminate tobacco use.  
1.1. Tobacco control: context and challenges 
Tobacco control is a global health priority. In 2003, the global tobacco control commitment 
was formalized with the adoption of the Framework Convention on Tobacco Control (FCTC). 
The FCTC is an international treaty that embodies worldwide prioritization of public health 
protection from the consequences of tobacco use and is aimed towards substantial and 
continuous tobacco use reduction. It stipulates obligations for the development, enactment, 
monitoring and evaluation of national tobacco control strategies, and includes measures for 
reducing tobacco consumption and availability with accompanying provisions and guidelines 
for implementation. In addition to concrete tobacco control measures, the treaty mandates 
up-to-date and comparable surveillance of the tobacco epidemic [3]. In 2011, the United 
Nations (UN) adopted the Political Declaration of the High-level Meeting of the General 
Assembly on the Prevention and Control of Non-communicable Diseases (NCDs) which 
placed the control of tobacco use and other NCD risk factors high on the international agenda 
[4]. The resolution recommended accelerated implementation of the full range of FCTC 
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measures and called for the World Health Organization (WHO) to develop a comprehensive 
global framework for trends monitoring and progress assessment [4]. This framework, 
adopted in 2013, is comprised of indicators that allow internationally comparable time trend 
assessments and provides voluntary country-level targets that would represent significant 
progress if achieved by 2025. These targets include a 30% relative reduction in current 
tobacco use [5].  
1.1.1. Global milestones in tobacco control 
Since the first US Surgeon General’s (USSG) report on the harmful effects of tobacco use, 
there have been significant advancements in the knowledge and tools for tobacco control. The 
1964 USSG report conclusively established a causal association between tobacco smoking 
and lung cancer [6] and led to further research on the consequences of tobacco use and 
interventions to reduce it. Landmark endeavors to comprehensively quantify tobacco-related 
health outcomes include Peto et al.’s study in the early 1990s [7] and the first incarnation of 
the Global Burden of Disease (GBD) studies in the latter part of that decade [8]. These 
assessments estimated about two million tobacco-attributable deaths in 1985 in developed 
settings alone [7] and 40 million tobacco-attributable disability-adjusted life-year (DALY) 
losses in 1990 worldwide [8], emphasizing tobacco use as a major global risk factor. Key 
evidence for combating the tobacco epidemic was provided in a comprehensive WHO 
cost-effectiveness analysis which identified a number of cost-effective interventions requiring 
government action [9]. Such evidence on both the magnitude of the tobacco epidemic and on 
cost-effective means to curb it were instrumental in the development and negotiation of the 
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FCTC [9, 10], which has been ratified by 180 countries since coming into effect in 2005 [11, 
12]. The WHO subsequently launched the MPOWER policy package in 2008. This consists 
of six components: “monitor tobacco use and prevention policies, protect people from 
tobacco smoke, offer help to quit tobacco use, warn about the dangers of tobacco, enforce 
bans on tobacco advertising, promotion and sponsorship, and raise taxes on tobacco” [13], 
and is aimed at assisting country-level FCTC implementation.  
1.1.2. Tobacco control measures 
Tobacco control can be categorized into demand reduction and supply reduction measures [3, 
14]. Major evidence-based demand reduction interventions stipulated in the FCTC and 
endorsed by the WHO include smoking bans, cessation support, health warnings, marketing 
regulations, and taxation [3, 13]. 
 
Smoking bans involve enactment of legislation for establishing smoke-free environments, 
which diminish opportunities to smoke [13]. There is evidence of the effectiveness of bans in 
public places for reducing exposure to second-hand smoke [15], cutting consumption among 
smokers [16], and even encouraging voluntary smoke-free policies in households [17]. 
Because having designated smoking areas can undermine impact [18] and weak enforcement 
can damage the credibility of smoking bans [19], the WHO recommends complete 
prohibition of smoking in all indoor environments with clear and reliably-imposed sanctions 
for violations [13]. 
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Cessation support, on the other hand, involves provision of services to help smokers 
overcome nicotine addiction and quit smoking. Forms of cessation support with evidence of 
effectiveness include pharmacological treatment, quit lines and integration of cessation 
services into primary health care [13]. Pharmacological treatment can help lessen withdrawal 
symptoms (e.g. nicotine replacement therapy), reduce cravings (e.g. bupropion) or diminish 
the pleasure response to nicotine (e.g. varenicline) [13, 20, 21]. Quit lines and primary 
care-level integration can reinforce these cessation efforts through counseling and active 
referral [22, 23]. To support these measures, the WHO recommends public funding for the 
costs of nicotine replacement therapy and/or clinical cessation services [13]. 
 
Health warnings on tobacco product packaging serve to increase awareness of the risks and to 
reduce the desirability of tobacco use to encourage cessation and prevent initiation [24]. The 
FCTC stipulates health warnings that cover at least 30% of the principal display area of 
tobacco product packaging [3]. Marketing restrictions consist of bans on tobacco product 
advertising (e.g. on television and radio) and promotion in order to protect non-users of 
tobacco products—especially young people—from tobacco companies’ efforts to attract new 
consumers and expand sales [13, 25-28]. These measures work in conjunction with health 
warnings to protect tobacco product users from the industry’s efforts to reinforce or even 
exacerbate their habits. Advertising bans have been found to be effective in reducing tobacco 
use [25, 29, 30] and the WHO recommends complete prohibition of all forms of advertising, 
promotion and sponsorship [13, 19, 25]. 
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The final demand reduction measure is increased taxation, which reduces demand by raising 
tobacco product prices beyond affordability, and has been found to be the single most 
effective means of decreasing consumption and encouraging cessation [19]. The WHO 
recommends >75% of the retail price of tobacco products be composed of taxes [13, 31]. 
Although the tobacco industry asserts that increased taxation causes illicit trade, a 
comprehensive review of evidence from the experience of many countries shows that any 
post-tax-increase shift to illegal tobacco products is minor and transient, and that the health 
and economic benefits of reduced tobacco use and increased tax revenues outweigh potential 
illicit trade consequences. Furthermore, assessments have shown that supply-side factors such 
as weak enforcement, corruption and organized crime are more important drivers of illicit 
trade and in any case, the appropriate solution is not to lower taxation but rather to strengthen 
anti-illicit trade measures [32]. 
 
A recent demand reduction innovation, plain cigarette packaging, strips cigarette packs of all 
branding and design in order to reduce appeal and enhance prominence of health warnings 
[33, 34]. This approach is based on evidence that packaging is an important element in how 
tobacco is perceived by users and non-users alike [33, 35]. Plain packaging was first 
implemented in Australia [36, 37], and is also underway in a number of other countries such 
as Ireland [38] and the United Kingdom [33, 34, 39].  
 
The FCTC also recommends supply reduction measures, which include action against illicit 
trade of tobacco products and crop substitution for tobacco farmers [3, 14]. In addition, 
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several supply-side innovations have been proposed in the past decade but have yet to be 
implemented [40]. These include novel frameworks within which tobacco products would be 
supplied such as Borland’s Regulated Market Model [41] and Callard and Collishaw’s 
“non-profit enterprise with public health mandate” [42]. Other innovations include Gilmore et 
al.’s proposed creation of the Office for Smoked Tobacco Regulation for imposing price 
controls at the production level [43] and Sugarman’s “performance-based regulations” 
involving legislated industry public health targets [44]. Eventual abolition of commercial 
tobacco sales through phasing-out in a “Sinking-Lid” approach [45] and absolute commercial 
bans [46] have also been proposed.  
1.1.3. Progress and remaining challenges 
Despite worldwide progress in the implementation of tobacco control measures and 
reductions in tobacco use prevalence, country disparities persist and tobacco smoking 
remains a leading global risk factor [47]. The 2013 WHO Global Tobacco Control Report 
(GTCR) estimates one-third of the world’s population—about 2.3 billion people in 92 
countries—to be covered by at least one MPOWER tobacco use reduction measure at the 
highest recommended level. This represents an increase in global tobacco control coverage of 
almost 1.3 billion people and 48 countries since 2007 [48]. 
 
However, population coverage and progress vary across individual MPOWER components. 
For instance, smoke-free policies covered 16% of the global population in 2012 due to 
adoption of complete smoking bans by 32 countries, corresponding to an increase of about 
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1.1. billion people protected since 2007. In contrast, the most cost-effective strategy of 
taxation to >75% of the retail price covered only 8% of the world population in 2012 and is 
the measure on which least progress has been made. Only ten countries raised taxes to the 
recommended rate, corresponding to an increase of 40 million people covered [48].  
 
Furthermore, the comprehensiveness and level of implementation of MPOWER measures 
vary across settings. For instance, a number of low- or middle-income countries in the WHO 
region of the Americas have all MPOWER measures in place and have achieved the highest 
recommended level for more than one intervention. In contrast, many vulnerable countries in 
the WHO African region lack several measures and those in place are mostly below the 
recommended levels [48]. Tobacco control efforts are also impeded by industry interference 
and vested government interests [49, 50]. Tobacco industry interference includes threats of 
expensive litigation such as those brought by large multinational tobacco companies like 
Philip Morris International against the resource-poor countries of Togo and Uruguay [49, 51, 
52]. Government ownership of tobacco companies such as Japan Tobacco can also impede 
implementation of strong tobacco control policies through conflicts of interest between 
commercial and public health imperatives [49, 50].  
 
Such country-level variation in tobacco control progress despite advances in global tobacco 
control efforts is also reflected in tobacco use prevalence patterns. Globally, daily tobacco 
smoking prevalence is estimated to have decreased from 41.2% to 31.1% among men and 
from 10.6% to 6.2% among women within the period 1980 to 2012 [53]. However, the rate of 
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decline has slowed in recent years due to growth in daily tobacco smoker numbers in 
populous countries like Bangladesh, China, Indonesia and Russia and the number of daily 
tobacco smokers increased from 721 million to 967 million within the same timeframe. A 
number of countries also continue to experience very high daily tobacco smoking prevalence 
in 2012 among both men (>50%) and women (>30%) [53]. 
 
Such continued tobacco use pervasiveness in turn translates to health outcomes. The most 
recent global burden of disease estimates attribute 18% of NCD deaths and 11% of NCD 
burden to tobacco smoking. These correspond to about 7 million NCD deaths and 144 million 
NCD DALY losses attributable to tobacco smoking in 2010, with the majority in developing 
settings [54]. Tobacco control efforts must be intensified in order to avert this health burden, 
and continuous monitoring is key to understanding what works and how to implement 
tobacco control measures. 
1.2. Challenges in monitoring tobacco use trends 
Monitoring tobacco use is crucial for assessing tobacco control efforts, and the FCTC 
mandates continuous surveillance and evaluation of control strategies [3]. However, various 
aspects of the tobacco epidemic present challenges for its measurement. 
1.2.1. Forms of tobacco use 
Tobacco is smoked or used in a smokeless manner. Tobacco smoking refers to inhalation of 
the smoke produced from combustion of dried or cured tobacco plant leaves. Smokeless 
tobacco use refers to consumption not involving combustion such as chewing, placement 
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within the oral cavity or sniffing [13, 55]. Both forms of tobacco use have been linked to 
harmful health effects although data on the less globally prevalent smokeless use is severely 
limited [55]. Tobacco smoking has been associated with cancer, lung disease and 
cardiovascular disease. Up to 90% of lung cancers have been found to be attributable to 
smoking [56] which has also been linked to oral, pharyngeal, laryngeal, esophageal and 
gastric malignancies [57-59]. Smoked tobacco use has also been associated with tuberculosis 
and lung dysfunction and injury [59], and has been shown to significantly increase risks for 
cerebrovascular disease [13, 57] and fatal myocardial infarction [13]. Though relatively 
limited in availability, studies on smokeless tobacco use have also provided evidence of 
associations with oral, esophageal, pancreatic and lung cancers [60]. Beyond the adverse 
consequences for its users however, tobacco smoking also poses health risks to non-users in 
the form of second-hand smoke (SHS) [61]. Such extended effects of smoked tobacco include 
mortality from lung cancer and cardiovascular disease [62] and adverse perinatal and 
pediatric outcomes such as pre-term deliveries [63], low birth weight [64], sudden infant 
death syndrome (SIDS) [65] and childhood asthma episodes [63]. Globally, tobacco smoking 
is the most prevalent form of tobacco use, and monitoring of trends in tobacco smoking is 
essential to understand the current and future risk profile that it poses. However, monitoring 
tobacco smoking requires an understanding of smoked product types. 
1.2.2. Smoked tobacco product types 
Smoked tobacco product types include cigarettes, cigars, pipes and water pipes. Cigarettes 
include manufactured types, roll-your-own (RYO) and local variants such as bidis, brus and 
  10 
kreteks [55, 66]. Modern manufactured cigarettes typically consist of a thin paper cylinder of 
finely-shredded non-fermented tobacco leaf blends. Most include reconstituted tobacco plant 
materials and additives—such as menthol for flavor—and contain cellulose acetate filters at 
the tip [55, 67]. RYO cigarettes are prepared by the user from loose tobacco and rolling paper 
[55]. Bidis consist of a small amount of tobacco flakes hand-wrapped and string-tied in leaves 
of the tendu or temburni plant which is native to Asia [55, 66, 68]. Brus contain sun-cured 
tobacco [55, 66] while kreteks contain a mixture of tobacco and cloves [55, 68]. Cigars on the 
other hand, typically consist of a roll of a single type of air-cured and fermented tobacco 
wrapped in tobacco leaf [55, 69, 70]. Pipes are devices consisting of a chamber for tobacco 
placement and combustion, and a hollow stem for smoke inhalation [55]. Water pipes consist 
of a perforated head for tobacco burning, a body for smoke passage, a water bowl for smoke 
filtration and a flexible hose and mouthpiece for smoke inhalation [55, 71].  
 
Although manufactured cigarettes are the most prevalent globally [55], other cigarette 
variants and smoked tobacco product types cannot be discounted due to their health risks and 
characteristic geographical distributions. Smoke from bidis and kreteks has higher nicotine, 
tar and carbon monoxide concentrations relative to that of conventional cigarettes [68, 72]. 
Bidis are also associated with increased risks of cancers (oral, esophageal, stomach and lung), 
cardiovascular disease (coronary heart disease and acute myocardial infarction) and lung 
disease (emphysema and chronic bronchitis), while kreteks are associated with increased risks 
of lung dysfunction and acute lung injury [59, 68]. Smoking other product types such as 
cigars and water pipes also involves a multitude of health risks similar to cigarette use [58, 59, 
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71]. Geographically, RYO cigarettes are prevalent in Europe and New Zealand [55], bidis are 
common in South Asia and heavily consumed in India [55, 68, 73], brus are local to Papua 
New Guinea [55], kreteks are widespread in Indonesia [55, 68, 73] and water pipes are 
customary in Northern Africa and the Eastern Mediterranean [55, 71, 73]. 
1.2.3. Electronic nicotine delivery systems 
Electronic nicotine delivery systems (ENDS), popularly known as e-cigarettes, are emerging 
tobacco use-related products that have garnered much attention and debate. E-cigarettes are 
battery-powered devices designed to provide an aerosol containing nicotine—the addictive 
substance in tobacco—for inhalation [74-77]. Since its development in China in 2003 [74], 
the ENDS industry has expanded into an estimated three billion US dollar market in 2014 
[77]. The sparse literature on its uptake shows, however, that lifetime use of ENDS is rare 
among those who have never smoked and prevalence of current use remains concentrated in 
current smokers and is very low relative to conventional tobacco smoking. Nationally 
representative samples of adults in the US and the UK estimate that less than one percent 
(0.8% in 2010 [78] and 0.5% in 2012 [79] respectively) of never-smokers have ever tried 
ENDS. The International Tobacco Control Four-Country Survey estimated 2.9% of current or 
former smokers (1.0% in Australia and in Canada, 4.0% in the UK, 6.0% in the US) were 
current ENDS users in 2010-2011 [80]. An estimated 6.7% of adult current smokers in the 
UK were also current ENDS users in 2012 [79]. There is only sparse evidence for both the 
potential benefits and risks of e-cigarette use and their long-term consequences cannot yet be 
concluded. Reviews have found evidence of its benefit as a smoking cessation aid. 
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E-cigarette vapors also contain carcinogenic and toxic substances, at lower levels than 
conventional cigarette smoke, but the risk of regular and prolonged exposure is difficult to 
estimate at present [74, 77, 81, 82]. 
1.2.4. Frequency of tobacco use 
Tobacco smoking frequency falls into two general categories: daily and non-daily. The WHO 
defines daily tobacco smokers as “individuals who smoke any tobacco product at least once a 
day, including those who smoke every day except days of religious fasting” [83, 84]. 
Non-daily or occasional smokers are in turn defined as “individuals who smoke any tobacco 
product, but not every day” [83, 84]. 
 
Both frequency categories carry significant health risks, although daily smokers typically 
comprise the majority of current tobacco users. Daily smoking even at low levels of 
consumption (e.g. one to four cigarettes per day) has been associated with significantly 
increased mortality risks from cancer, heart disease and all causes [85, 86]. However, even 
occasional smoking has been shown to significantly increase cardiovascular and all-cause 
mortality risks relative to non-smokers [87]. There is also evidence that occasional smoking 
can become a persistent and regular habit [88, 89] and that lengthy duration of such behavior 
significantly heightens the risk of lung cancer. Lung cancer risk has been shown to be more 
dependent on smoking duration rather than intensity. The exposure-risk relationship has been 
found to plateau with increasing intensity but to continue to increase with longer duration [90, 
91]. 
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Occasional smokers can also comprise substantial proportions of current tobacco users in 
both developed and developing settings. In the US for instance, non-daily smoking has 
increasingly become an established pattern in recent years with about one-third of those who 
currently smoke doing so occasionally [92]. The fraction of non-daily smokers can be even 
higher in developing settings, even comprising the majority of tobacco smoking in some 
countries. In Mexico for example, non-daily smokers comprised 64.4% of current smokers 
for men and 70.2% for women in 2003 [93], and 52.4% of current smokers for men and 
52.6% for women in 2009 [94]. Likewise in 2011, 55.0% of men and 59.3% of women who 
currently smoke did so occasionally [95]. It is thus important to account for both daily and 
non-daily frequency in measuring tobacco use. 
1.2.5. Measurement of tobacco use 
Tobacco use may be measured in terms of prevalence and/or consumption. Prevalence, 
measuring the proportion of the population who smoke, is a straightforward yet meaningful 
indicator of the extent of the smoking epidemic in a population. Prevalence estimation among 
subpopulations provides crucial information on the progression and differential uptake of 
smoking behavior among sexes and within age groups. Consumption on the other hand, 
measures the average number of tobacco products smoked per individual over a certain 
period of time. It can provide a more detailed description of smoking intensity, which 
indicates the amount and frequency of tobacco product consumption. 
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Of these two measures however, prevalence is a more comprehensive indicator of population 
exposure to smoking hazards and is also more important for public health purposes. 
Consumption measures cannot be used to track the diffusion of smoking behavior throughout 
a population nor approximate the extent of SHS exposure. Consumption is also more strongly 
influenced by disposable income such that fluctuations are not always entirely attributable to 
tobacco control interventions [83, 96]. Although smoking intensity determines magnitude of 
health risks, even very low levels of consumption carry significant health hazards to both 
users and non-users [85-87], and thus promoting cessation or preventing initiation altogether 
are the ultimate goals of public health efforts. 
 
For public health purposes, prevalence of current use is deemed the most important indicator 
by the International Agency for Research on Cancer (IARC) [83] and is also rated as a key 
outcome indicator by the US Centers for Disease Control and Prevention (CDC) [97]. It is 
determined primarily by rates of initiation and cessation which are the major focus of tobacco 
control strategies in order to reduce the hazards of tobacco use or exposure to its smoke [83]. 
Reduction of prevalence of current use is also the target set in the WHO global monitoring 
framework [5]. 
 
In addition, WHO tobacco control monitoring guidelines recommend that frequency of use be 
measured such that current users are divided into daily and non-daily subgroups [83]. Daily 
and non-daily use prevalence information is useful because frequency is a predictor of 
cessation [98]. Finally, the IARC also deems prevalence of use of different product types to 
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be important due to the varied geographical distributions of different tobacco products [83]. 
Both frequency and product type should thus be taken into account in monitoring efforts.  
1.3. Previous tobacco use assessment efforts 
Although literature on tobacco use prevalence estimates, trends and projections for certain 
regions and countries are available, there remains a need for a comprehensive and consistent 
assessment of various tobacco use prevalence indicators encompassing historical trends, 
future projections and target achievement based on the most up-to-date information. 
 
Early endeavors to assess the extent of the tobacco epidemic were limited by data scarcity, 
especially in developing settings. The 1997 WHO Tobacco or Health: Global Status Report 
attempted to provide comprehensive and comparable country-specific tobacco use indicator 
estimates for the early 1990s. However, the assessment was based on prevalence data from 87 
countries involving only 29.4% of developing nations, and there were striking regional 
disparities in data availability at the time. For instance, relatively few countries from the 
WHO African and Eastern Mediterranean regions had usable prevalence information. Only 
daily smoking prevalence estimates could be provided due to data limitations despite WHO 
recommendations to include current and non-daily smokers in tobacco use assessments, and 
uncertainty was not quantified [66]. 
 
However, data availability has improved substantially since then, especially in developing 
settings. Over the first decade of the 2000’s for instance, 49 Demographic and Health 
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Surveys (DHS) including tobacco use information were implemented in low- or 
middle-income countries, including 25 African nations [73], and the WHO STEPwise 
approach to surveillance (STEPS) NCD Risk Factor Surveys were conducted in 94 countries 
across all WHO regions, including 36 countries from Africa [99]. Furthermore, the Global 
Tobacco Surveillance System (GTSS), including the Global Adult Tobacco Surveys (GATS), 
was launched in 2007 and has since been implemented in 19 of the highest tobacco burden 
low- or middle-income nations [100]. 
 
More recent tobacco use assessments have capitalized on such improved data availability. 
The WHO GTCR series has provided country-specific smoking prevalence estimates 
considering both product type and frequency but only for individual time points with the most 
recent available data. These reports do not provide a systematic assessment of time trends or 
uncertainty intervals [48]. Estimates have also been based on an old model that relies heavily 
on regional patterns—even for countries with good data—for assessing product type and 
frequency characteristics and for describing age patterns in prevalence [101]. The Institute for 
Health Metrics and Evaluation (IHME) estimated tobacco use prevalence trends from 1980 to 
2012 but only for a measure of daily smoking that does not account for all current tobacco 
users [53]. Assessment of only daily smoking prevalence may underestimate the magnitude 
and threat of the tobacco epidemic in crucial settings such as developing countries with 
substantial proportions of non-daily smokers at higher risk of greater tobacco use addiction 
and intensity [93-96]. Neither this study nor the WHO GTCR series made projections [48, 
53]. 
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A 2012 Mendez et al. study developed global smoking prevalence trajectory estimates for 
2020 and for 2030, but this study only focused on 60 countries and current cigarette use and 
did not make separate assessments by sex. Including only the ten nations with the highest 
number of current cigarette smokers in each WHO region overlooks countries with low 
smoking prevalence at present but which are at risk of full-blown tobacco epidemics in the 
future. By looking only at current smokers, this study neglected changes in frequency of 
tobacco use, which is a useful indicator of smoking epidemic stages or tobacco control 
effectiveness. Assessing only cigarette use in this study underestimates prevalence due to 
other forms of smoked tobacco and non-sex-specific estimates could overlook diverging 
trends in population subgroups [102]. 
 
A 2014 modeling exercise by Kontis et al. made global projections to 2025 but did not assess 
country-specific tobacco use reduction target achievement. The study also used an indirect 
measure of smoking exposure based on lung cancer mortality called the smoking impact ratio 
(SIR) [103], which does not provide a comprehensive understanding of trends in tobacco use. 
Although the SIR captures accumulated smoking exposure involving various smoking 
behavior characteristics, its measurement involves additional assumptions such as 
applicability of the choice of reference population [104]. It is also a less sensitive and timely 
measure of the full extent of smoking exposure and hazards in a population compared to 
current, daily and occasional smoking prevalences which are of higher interest for tobacco 
control programs [83, 96]. This is because lung cancer mortality rates can continue to 
increase or plateau even though smoking prevalence or frequency is declining [90, 96].   
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1.4.  Objectives 
To maintain global progress and reduce country disparities in averting preventable 
tobacco-attributable health burden, up-to-date, comprehensive and consistent country-level 
assessment of trends and projections of key tobacco use indicators and of target achievement 
are indispensable. Country-level trend monitoring is required by the FCTC [3] and is a 
component of the WHO MPOWER policy package [13, 105]. It is essential for identifying 
transitions in the state of the tobacco epidemic, assessing local tobacco control progress, 
benchmarking against peers or global leaders, and setting national goals. Projections are 
helpful in determining whether countries are on track towards achievement of goals and in 
gauging remaining challenges that must be overcome. Measurement of different tobacco use 
indicators—such as those involving frequency and product types—provides a more 
informative picture of the situation in various settings and ensures that smoking hazards in 
countries with idiosyncratic tobacco use characteristics (e.g. popularity of local cigarette type, 
high proportion of occasional smoking) are not neglected. 
 
To achieve these goals, this study aimed to provide a comprehensive and consistent 
assessment of recent trends and projections for four tobacco use indicators and of target 
achievement under the WHO global monitoring framework for as many countries as feasible. 
The specific objectives were to: 
• Describe time trends from 1990 onwards in four tobacco use indicators: current 
tobacco smoking, daily tobacco smoking, current cigarette smoking and daily 
cigarette smoking 
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• Make projections to 2025 for all four indicators assuming recent trends persist 
• Estimate the probabilities of decreasing tobacco use, increasing tobacco use and 
achieving a 30% reduction in current tobacco smoking by 2025 relative to 2010 levels 
 
This information can provide valuable insights for prioritization, resource allocation, 
intervention design and implementation, and formulation of national policies and future 
tobacco control strategies. Assessment of target achievement probabilities under the WHO 
global monitoring framework is useful for reinforcement of political commitment, awareness 
raising and advocacy, and can provide motivation for accelerating action and progress. A 
comprehensive and consistent global perspective is helpful in identifying not only countries 
and regions in need of greater tobacco control support but also those that can serve as models. 
These assessments provide important tools for maintaining and accelerating progress towards 
global convergence in target achievement and tobacco use elimination. 
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2. METHODS 
A Bayesian hierarchical modeling approach was developed using tobacco use prevalence data 
from the WHO Comprehensive Information Systems for Tobacco Control (CIC). Trends for 
four tobacco use indicators—current tobacco smoking, daily tobacco smoking, current 
cigarette smoking, and daily cigarette smoking—were assessed from 1990 to 2010, baseline 
projections were made to 2025 and probabilities for decreased tobacco use, increased tobacco 
use, and achievement of tobacco use reduction targets were obtained. This chapter presents 
details on data, inclusion and exclusion criteria, operational definitions and analytic approach. 
2.1. Data 
Data on tobacco use prevalence was obtained from the WHO-CIC unit which performs 
tobacco-related risk and outcome surveillance and monitoring using publicly-available, high 
quality survey data collected at the national level. 
2.1.1. Data sources 
The WHO-CIC, with involvement of WHO Region and Country Offices, conducts an 
extensive search for surveys that measure tobacco use in some form. For this project, 
identified data sources include: 
• Internationally-standardized surveillance systems and surveys—such as the GATS 
[100] component of the WHO GTSS, the WHO STEPS [99], the World Health 
Surveys [106], and the DHS [107] 
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• Region- or country-wide surveillance systems and surveys such as the Eurobarometer 
Surveys [108], the US Behavioral Risk Factor Surveillance System (BRFSS) [109], 
the Canada Tobacco Use Monitoring Survey (CTUMS) [110], the Japan National 
Health and Nutrition Surveys [111], and the Indonesian Basic Health Research 
surveys [112], and 
• Country reports of survey estimates, submitted to the WHO FCTC Secretariat, which 
are used to identify original survey sources to extract data from 
All data sources obtained are in the public domain.  
2.1.2. Data quality control 
Data quality control was conducted by the WHO-CIC unit with the involvement of WHO 
Region and Country Offices. Identified surveys were assessed according to WHO standards 
for adequacy of sample size and appropriateness of sampling methodology before results 
were used in order to ensure reliability of estimates and national representativeness. Data 
entry into the CIC database was conducted centrally to ensure consistency and compliance 
with WHO definitions and data requirements for the different tobacco use indicators. 
Prevalence estimates were entered into the dataset at the most disaggregated level (e.g. 
age-sex-specific) available. WHO Region and Country Offices were also engaged to provide 
more detailed information where feasible when reported estimates were highly aggregated 
(e.g. across all ages). Checking, investigation with corresponding country representatives and, 
if necessary, corrections were conducted for potential duplicates and errors. These involve 
extreme values (e.g. zeroes or >60% prevalences), higher reported prevalence values for 
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women relative to men, and inconsistencies between different indicators such as daily 
smoking prevalences higher than corresponding current smoking values for the same tobacco 
product type and cigarette smoking prevalences higher than corresponding all-tobacco 
smoking values for the same frequency category (i.e. current or daily). Some within-country 
prevalence variability due to differences in survey design over time however—such as 
changes in questionnaires or in outcome definitions even within survey waves as in the case 
of the Japan National Health and Nutrition Surveys—may not have been fully accounted for 
by the data quality control efforts. 
2.2. Inclusion and exclusion criteria 
For this analysis, a data source was included if it: provided country survey prevalence 
estimates for one or more of four tobacco use indicators (current tobacco smoking, daily 
tobacco smoking, current cigarette smoking, daily cigarette smoking); involved 
randomly-selected participants representative of the general population; and was officially 
recognized by the national health authority. A data source was excluded if it: was earlier than 
1990, was not nationally representative (e.g. urban/rural only, geographic/political 
subdivision, subpopulations such as students only) or if the maximum age of target 
participants was below 15 years. The dataset for this analysis encompasses 896 surveys, 180 
countries, and years from 1990 to 2014, amounting to 26,153 country-year-sex-age-specific 
datapoints. Details of surveys used in this analysis are provided in the WHO global report on 
trends in prevalence of tobacco smoking [113]. 
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2.3. Operational definitions 
This study calculated tobacco use for four indicators, and used groupings of countries for 
analytical purposes. Tobacco use indicators were defined in terms of product type and 
frequency, and country groups were defined based on tobacco epidemiology and geography. 
2.3.1. Product type 
Tobacco products in this study are classified into two subcategories: cigarettes and 
non-cigarettes. “Tobacco” refers to the overall outcome envelope inclusive of all smoked 
tobacco product types encountered in the surveys such as cigarettes, cigars, pipes, and water 
pipes. “Cigarette” refers to a subcategory of “tobacco” which excludes non-cigarette types 
(e.g. cigars, pipes, water-pipes) and includes only cigarette types encountered in the surveys 
such as manufactured cigarettes, roll-your-own cigarettes, or local cigarette variants (e.g. 
bidis in South Asia, brus in Papua New Guinea, kreteks in Indonesia). Such categorization 
capitalizes on the availability of cigarette-only survey data and although cigarettes tend to be 
the most commonly used form, estimation of both the overall “tobacco” envelope and its 
“cigarette” subcategory also provides an estimate of the complement “non-cigarette” 
subcategory which comprise a considerable proportion of tobacco use in certain settings (e.g. 
water-pipes in the Eastern Mediterranean). ENDS, although colloquially known as 
“electronic cigarettes,” do not contain tobacco [74] and are thus excluded from the tobacco 
use definition.  
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2.3.2. Frequency 
This study used the two commonest definitions of frequency, current and daily smoking. 
Current is defined as smoking at least once in the 30 days prior to the survey. Daily is defined 
as smoking at least once per day during the same 30-day period. The majority (>75%) of 
surveys included in this analysis measure only established tobacco use. Use is deemed to be 
established when a cumulative lifetime threshold is breached, in order to exclude those who 
are only experimenting [83].  
2.3.3. Analytic country groupings (“Regions”) 
For analytic purposes, countries were categorized into 21 regions reflective of tobacco 
epidemiology and geography. These combined tobacco use patterns and control history with 
the United Nations geoscheme subregions [48, 53, 114]. For example, Central Asian 
countries which were former states of the Soviet Union were grouped together with Russia 
and other Eastern European nations due to their geographical proximity and similar tobacco 
use culture and control history. The detailed country groupings are provided in Table 1. 
 
The choice of country groupings was decided on the basis of sensitivity analyses conducted 
to compare different ways of supplementing country data with regional information before 
the final model runs. The sensitivity analyses compared country groupings based only on 
tobacco control policies irrespective of geography (e.g. having Australia, New Zealand and 
Canada in the same group) against groupings which accounted for both tobacco epidemiology 
and geography (e.g. good tobacco control countries such as Australia and New Zealand 
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grouped together but separated from nearby developing nations in the Western Pacific with 
high smoking prevalences such as Papua New Guinea). For each of these two main types of 
country groupings, different assumptions about within-group variability were also compared. 
One assumption was low within-group variability, with a consequent strong group influence 
on country estimates. A contrasting assumption was moderate within-group variability, such 
that countries with good data were robust to group influences while countries with scarce data 
followed group trends to a certain extent. 
 
Diagnostics summarized in Appendix E showed that models based on country groupings 
accounting for both geography and tobacco use epidemiology with moderate within-group 
variability performed best overall. Although some countries with different socioeconomic 
histories such as China and Japan were grouped together, such a grouping reflects a general 
East Asian tobacco use pattern of high prevalence among men and relatively very low 
prevalence among women. Furthermore, final model diagnostics displayed good model 
performance, as shown by high coverage and low RMSEs. 
  26 
Table 1: Analytic country groupings 
Region Countries 
Africa, Central Cameroon, Congo, Democratic Republic of the Congo, Gabon, Sao Tome and Principe, Chad 
Africa, East Burundi, Djibouti, Eritrea, Ethiopia, Kenya, Mozambique, Malawi, Rwanda, United Republic 
of Tanzania, Uganda, Zambia, Zimbabwe 
Africa, East Islands Comoros, Madagascar, Mauritius, Seychelles 
Africa, North Algeria, Egypt, Libya, Morocco, Tunisia 
Africa, South Botswana, Lesotho, Namibia, Swaziland, South Africa 
Africa, West Benin, Burkina Faso, Cabo Verde, Cote d’Ivore, Ghana, Guinea, Gambia, Liberia, Mali, 
Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo  
America, Central Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama 
America, North Canada, United States of America 
America, South Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, 
Uruguay, Venezuela 
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Table 1: Analytic country groupings (continued) 
Region Countries 
Asia, East China, Japan, Republic of Korea, Mongolia 
Asia, South Bangladesh, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka 
Asia, Southeast Brunei Darussalam, Cambodia, India, Lao People’s Dem. Rep., Malaysia, Myanmar, 
Philippines, Singapore, Thailand, Timor-Leste, Viet Nam 
Asia, West United Arab Emirates, Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, West Bank and Gaza 
Strip, Qatar, Saudi Arabia, Syrian Arab Republic, Yemen 
Australasia Australia, New Zealand 
Caribbean Bahamas, Barbados, Cuba, Dominica, Dominican Republic, Granada, Haiti, Jamaica, Saint 
Kitts and Nevis, Trinidad and Tobago, St. Vincent and the Grenadines 
Europe, East Armenia, Azerbaijan, Bulgaria, Belarus, Czech Republic, Estonia, Georgia, Hungary, 
Kazakhstan, Kyrgyzstan, Lithuania, Latvia, FYR Macedonia, Poland, Romania, Russian 
Federation, Slovakia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan 
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Table 1: Analytic country groupings (continued) 
Region Countries 
Europe, North Denmark, Finland, Ireland, Iceland, Norway, Sweden, the United Kingdom 
Europe, South Albania, Andorra, Bosnia and Herzegovina, Croatia, Cyprus, Greece, Israel, Italy, Malta, 
Portugal, Serbia, Slovenia, Spain, Turkey 
Europe, West Austria, Belgium, France, Germany, Luxembourg, Netherlands, Switzerland 
Greenland Greenland 
Polynesia Cook Islands, Fiji, Kiribati, Marshall Islands, Niue, Nauru, Palau, Papua New Guinea, 
Solomon Islands, Tonga, Tuvalu, Vanuatu, Samoa 
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2.4. Analysis 
2.4.1. Analytic challenges 
The analysis for this research involved several challenges. Data was scarce for a number of 
countries especially in developing settings; available data was in non-standard age categories; 
and information from different studies and for different tobacco use indicators had to be 
incorporated into a single analytical framework. Furthermore, estimates were required to 
have consistency between indicators, meaning current tobacco smoking must serve as the 
overall envelope for prevalence, daily tobacco smoking and current cigarette smoking must 
not be greater than that envelope, and daily cigarette smoking must not be greater than any of 
the other indicators. 
 
The former statistical model used by the WHO-CIC for tobacco use prevalence estimation 
employed classical or frequentist regression [101] and the general methodological approach 
had a number of shortcomings. The frequentist framework involved inability to produce 
robust estimates for countries with scarce data. Other limitations included excessive influence 
of regional tobacco use patterns on country-specific prevalence estimates even for settings 
with good data due to crude methods for selecting regional age patterns. There was also no 
internal mechanism for adequately preventing inconsistent or illogical estimates for the 
various tobacco use indicators (e.g. daily smoking values higher than current smoking values 
or cigarette smoking values higher than all-tobacco smoking values). Furthermore, the 
previous methodological approach did not account for differences in sampling design of data 
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from different surveys. To overcome these problems, a constrained Bayesian meta-regression 
modeling approach was developed that enabled robust estimation even with scarce data, 
provided more control over the influence of regional tobacco use patterns, incorporated 
meaningful constraints on the relationship between indicators and adjusted implicitly for 
sampling design. 
 
2.4.2. Analytic approach 
To address this study’s analytic challenges, a Bayesian hierarchical meta-regression modeling 
approach incorporating a flexible age structure was developed. Bayesian statistics utilizes 
observed data together with additional information about the theoretical distribution of 
parameters in the statistical model, usually represented through a distribution of the 
parameter called a “prior distribution”, which expresses the current state of knowledge about 
the mathematical form and likely values of that parameter. The priors are combined with the 
assumed probability distribution of the data, termed the “likelihood”, to arrive at “posterior” 
distributions from which are obtained summary measures for the quantities of interest. 
Hierarchical modeling is a modeling framework where distribution parameters are themselves 
assigned probability distributions determined by “hyperparameters” [115, 116]. In standard 
Bayesian statistical models, this enables a statistical model to be adjusted based on 
information obtained about the parameters of the model from pre-existing statistical, medical 
or other literature that can inform interpretation of the data. In this study, prior distributions 
were generated based on each country’s region, and these priors allowed us to supplement 
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scarce country data with regional information, and to specify constraints for simultaneous and 
consistent estimation of different tobacco use indicators. The meta-regression component 
enabled incorporation of data from various studies and addressed systematic differences 
between data sources. To utilize data from different studies with non-standard age categories, 
the model used a flexible spline structure for age, from which estimation was performed at 
desired age intervals. 
 
Compared to the previous WHO method, this Bayesian hierarchical meta-regression 
modeling approach had several advantages. These improvements provided a formal statistical 
framework for using regional information to supplement country data in such a way that 
estimates followed observed country-specific tobacco use patterns more accurately for 
settings with good data and also allowed robust estimation for countries with scarce data. 
Unlike the former model, this new approach also featured a built-in mechanism for ensuring 
logical and epidemiologic consistency between the different tobacco use indicators. Finally, 
the meta-regression component accounted for differences in sampling design encountered 
when using data from different surveys which were not addressed by the previous method. 
  
2.4.3. Bayesian hierarchical framework 
The Bayesian hierarchical framework used for this analysis is summarized in the directed 
acyclic graph (DAG) shown in Figure 1. 
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Figure 1: DAG of Bayesian hierarchical framework for tobacco use modeling 
 
In the DAG, model variables are represented by nodes drawn as geometric shapes following 
the PyMC notation [117]. Stochastic quantities (i.e. variables that are assigned probability 
distributions) are represented by ovals and deterministic quantities (i.e. those defined by 
mathematical functions) are represented by triangles. Shaded shapes are observed quantities 
[117]. Arrows represent dependence between quantities, described as “parent-child 
relationships”. Parents are nodes from which arrows emanate and children are nodes where 
arrows terminate [116, 117]. For example, the nodes γ and π(a) are in a “parent-child” 
relationship with the deterministic quantity π(a) as the “child” being dependent on the value 
of and uncertainty around its “parent” stochastic quantity γ. In turn, π(a) is also a “parent” 
with a “child” π which depends on it and π’s other “parents” β and α.    
 
The expected prevalence π is the prime objective for estimation and projection in this study. 
 
 
 
 
 
  
π(a) 
π 
δ 
η 
n 
p 
γ
β
α
~ Negative binomial 
~ Uniform 
~ Normal 
~ Normal 
~ Normal 
  33 
The observed value of the prevalence, p, is assumed to have a negative binomial distribution 
with parents π, δ and n. π is the expected value of prevalence, δ is the dispersion parameter 
and n refers to effective sample size. δ has parent η, the base overdispersion parameter, which 
is assigned a uniform prior. The parents of π are the set of α, β and π(a). The α country-level 
random effects and β regression fixed-effect coefficients are assigned normal priors. The 
function π(a) denotes an age-specific piecewise linear spline which has a set of parent γ’s. 
These γ’s are fixed-effect age coefficients that also have normally distributed priors.  
2.4.4. Data likelihood and regression model structure 
Model specification was conducted using DisMod-MR software, which is a Bayesian 
meta-regression tool originally developed by the IHME for the Global Burden of Disease 
(GBD) 2010 studies. Meta-regression here refers to analyzing data from different studies 
involving weighting with their effective sample sizes. DisMod-MR was used for efficient 
estimation at desired age-intervals in order to handle inputs in non-standard age categories. 
Technical details of the tool have been published elsewhere [118, 119] and are also provided 
below. In this implementation, data on the number of smokers, pn, was modeled using a 
generalized negative binomial likelihood. The negative binomial is a robust alternative to the 
conventional Poisson model for count data and is able to handle situations involving zero 
counts as well as overdispersion. In the DisMod-MR package, the probability density 
function for the negative binomial distribution was reparameterized such that the observed 
number of successes is equal to the product of the observed value of the prevalence and the 
effective sample size, pini, as given in Equation 1. 
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p !! !! , !! ,!! !∝ ! ! !!!! !!!! !! ! !!!!!!!!! !! !!!!!!!!!!! !!!!    (1) 
 
Where p is the observed value of the prevalence, π is the expected value of the prevalence, δ 
is the dispersion, n is the effective sample size and Γ is the gamma function. Effective sample 
size accounts for sampling design and is the sample size that would provide the same 
precision obtained in the study as would have been produced by a simple random sample 
[120]. 
 
To address the lack of a theoretical upper bound for the negative binomial, expert priors were 
specified to constrain prevalence within 0 and 1. Technical details of the implementation of 
expert priors in DisMod-MR are provided elsewhere [118, 119]. Although it is possible for 
the variance to continue to increase with the mean for the negative binomial distribution and 
potentially overstate the uncertainty around estimates, this risk is only a significant concern 
for prevalences greater than 50%, which are rare in the dataset (6% of datapoints). 
 
In this analysis, δ was determined by an informative prior on the base overdispersion 
parameter η (Equation 2), which specifies how much the model is restricted from following 
what is deemed to be “noise” in the data [118, 119].  !! = !!     (2) 
 
With prevalence as outcome, the regression model included several features. First, it involved 
time trend assessment for two decades of analysis that allowed for shifts in the most recent 
  35 
period. Also, it enabled simultaneous and consistent estimation for four tobacco use 
indicators. Finally, the model used a flexible age structure that allowed for diverse age 
patterns in different settings. The regression functions determining π in this analysis are 
shown in Equations 3 and 4 for regional and country models respectively.  !! = ! !!!!!!!!! !"!! !!!!!"#$!!!!!!! !!"#$%&!!!!!"#$×!"#$%&!!!!!"#$!!!!!"#!!!!!!"#$!!     (3) !! = ! !!!!!!!!! !"!!!!"#$!!!!!"#$%&!!!!!"#$×!"#$%&!!!!!"#$!!!!!"#!!!!!!"#$!!     (4) 
 
In the exponential function, αj’s are random effects at the country level to allow for 
variability between countries due to unmeasured factors. βtime and βperiod are regression 
fixed-effect coefficients for time (X1) and period (X2) variables. The period variable 
represents a split between two decades of analysis at the year 2000. βtimexperiod is an interaction 
term between time and period (X3) allowing for potential shifts due to country-level changes 
in time-varying factors such as tobacco control measure implementation.  
 
βsmkd, βcigc and βcigd are regression fixed-effect coefficients for dummy variables (X4, X5, X6) 
for daily tobacco smoking, current cigarette smoking and daily cigarette smoking respectively 
using current tobacco smoking as the reference category. The assumption of parallel trends 
over time across all four tobacco use indicators may not hold true for every setting. However, 
data limitations preclude the robust estimation of time and tobacco use indicator interactions 
at our analytical levels of interest and sensitivity analysis pooling data at the global level in 
previous research found no significant differential time trends across tobacco use definitions 
[53]. 
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In equations (3) and (4), π(a) is an age-specific piecewise linear spline with knots specified at 
15, 20, 30, 40, 50, 60, 70, 80 and 100 chosen in consultation with WHO tobacco and 
statistical experts in order to capture diversity and detail in age patterns in different settings. 
The knots have corresponding regression fixed-effect coefficients for age (γ’s). Technical 
details of the age-specific piecewise linear spline are provided elsewhere [118, 119]. Given a 
set of model-specific knots {a1, …, aK}, π(a) is defined in DisMod-MR as  π a = !! + !!!![! ≥ !!]!!!!   (6) 
where ! ! ≥ !! = 1, !"!! ≥ !!0, !"ℎ!"#$%! 
γk’s are age fixed-effect parameters 
 
Integrating over π(a) from the start (asi) to the end (aei) of the age interval for the ith 
observation gives the expected value of prevalence for that age interval which is further 
modified by the exponential function to yield the expected value of prevalence for the ith 
observation πi. While the age-specific piecewise linear spline enables the model to fit 
non-standard input age categories and provides flexibility in modeling age patterns, its 
current implementation in the DisMod-MR package precludes incorporation of an interaction 
between age and time. Although the assumption of a general age pattern over time may not 
be ideal for settings with rapidly changing age trends in prevalence, predictive accuracy 
checks show that our modeling strategy performs well for the majority of countries. 
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2.4.5. Consistency between indicators 
To ensure consistency between the different indicators, constraints were implemented in the 
form of priors on the dummy variable coefficients. Three indicators (daily smoking, current 
cigarette smoking, daily cigarette smoking) were constrained to be no greater than current 
smoking. Furthermore, daily cigarette smoking was constrained to not be greater than either 
daily smoking or current cigarette smoking. Technical specifications of the constraints are 
provided in Table 2. 
2.4.6. Model-building algorithm 
The model-building algorithm developed for this analysis was conducted separately for men 
and women and involved three consecutive model-fitting stages as follows:  
1. First-stage regional parameter estimates were fitted with the model structure given in 
Equation 3. Constraints were implemented in the form of priors on the dummy 
variable coefficients to ensure that daily tobacco smoking, current cigarette smoking 
and daily cigarette smoking cannot be greater than current tobacco smoking. This step 
generated regional estimates for informing time trend and tobacco use indicator 
relationships for subsequent country fits. 
2. Second-stage country estimates were then generated using the model structure given 
in Equation 4 and the same constraints on dummy variable coefficients as step 1. 
Time trends and tobacco use indicator relationships were informed by priors from the 
regional fit by using regional estimates from step 1 as hyperparameters for assumed 
distributions of the parameters in Equation 4. This step generated additional priors 
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restricting the value of daily cigarette smoking relative to both daily smoking and 
current cigarette smoking. 
3. Final models for all countries were fitted with the same model structure as, and 
similar constraints to step 2. Time trends and tobacco use indicator relationships were 
informed by priors from previous steps with a modified constraint to ensure that daily 
cigarette smoking cannot be greater than either daily smoking or current cigarette 
smoking. 
Details of the country groupings and of the prior assumptions used in the analysis are 
provided in Table 1, Table 2, Appendix A and Appendix B. Hyperparameters for η, π(a), γ's 
and the regional fit parameters were assumed a priori while those for the country-level 
models were mainly derived from previous fits. 
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Table 2: Prior specifications 
Parameter Assumed 
distribution 
Hyperparameters Type 
General  
η Uniform a 1 Informative 
  b 9  
π(a) N/A γ15 15 Informative 
  γ20 20 Informative 
  γ30 30 Informative 
  γ40 40 Informative 
  γ50 50 Informative 
  γ60 60 Informative 
  γ70 70 Informative 
  γ80 80 Informative 
  γ100 100 Informative 
γ's Normal µ 0 Non-informative 
  σ 1  
Regional fits  
αj's, βtime, 
βperiod, 
βtimexperiod 
Normal µ 0 Non-informative 
  σ 1  
βsmkd, βcigc, 
βcigd 
Truncated normal µ 0 Non-informative 
  σ 1  
  Upper 0  
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Table 2: Prior specifications (continued) 
Parameter Assumed distribution Hyperparameters Type 
Country fits  
βtime, βperiod, 
βtimexperiod 
Normal µ Appendix A 
Appendix B 
Informative 
  σ 0.25  
βsmkd, βcigc, 
βcigd 
Truncated normal µ Appendix A 
Appendix B 
Informative 
  σ 0.25  
  Upper 0 (second-stage) 
Country priors 
 
 
2.4.7. Model-fitting and implementation 
Calculations were performed in log space. Models were fitted by applying Markov Chain 
Monte Carlo (MCMC) methods with 10,000 iterations, discarding the first 5,000 and keeping 
every fifth iteration thereafter. Resulting final sets of 1,000 iterations approximated the 
posterior distributions of the parameters of interest. MCMC simulations were implemented in 
the Python programming language using the PyMC package [117].  
2.4.8. Prevalence estimation, projections and probabilities 
Models by country and sex were fitted separately to allow for potentially diverging trends 
between men and women. Trend estimates were obtained for the period 1990-2000 and 2000 
onwards, carrying the post-2000 trend forward to provide projections for all four indicators to 
2025. One thousand draws per year of age were generated from the resulting posterior 
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distributions of parameters. Numbers of smokers were obtained by multiplying prevalence 
and population estimates [121]. The WHO standard population [122] was used to obtain 
aggregated, age-standardized prevalences for ages 15 years and older. Means and uncertainty 
intervals from 2.5th and 97.5th percentiles were estimated from the distributions of these 
replicates. Quintiles of mean prevalence were calculated for 2000, for 2010 and for 2025. 
Relative percentage changes from 2000 to 2010 and from 2010 to 2025 were calculated. 
Posterior probabilities of decrease, increase and target achievement were obtained from the 
2010-2025 relative change distributions. A ≥95% posterior probability of decrease means that 
at least 95% of the simulated percentage changes are below zero. Summaries were reported 
by WHO region and World Bank income category as described in Table 3.
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Table 3: WHO region descriptions 
WHO region Acronym Income category Countries with model results 
WHO African Region AFR High-income None 
  Low- or middle-income Algeria, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cabo Verde, 
Chad, Comoros, Congo, Cote d'Ivoire, Democratic Republic of the Congo, 
Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Kenya, Lesotho, Liberia, 
Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, 
Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra 
Leone, South Africa, Swaziland, United Republic of Tanzania, Togo, 
Uganda, Zambia, Zimbabwe 
WHO Region of the 
Americas 
AMR High-income Bahamas, Barbados, Canada, Chile, Saint Kitts and Nevis, Trinidad and 
Tobago, United States of America, Uruguay 
  Low- or middle-income Argentina, Belize, Bolivia, Brazil, Colombia, Costa Rica, Cuba, Dominica, 
Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, 
Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint 
Vincent and the Grenadines, Suriname, Venezuela 
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Table 3: WHO region descriptions (continued) 
WHO region Acronym Income category Countries with model results 
WHO Eastern 
Mediterranean 
Region 
EMR High-income Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates 
  Low- or middle-income Djibouti, Egypt, Iran, Iraq, Jordan, Lebanon, Libya, Morocco, Pakistan, 
Syrian Arab Republic, Tunisia, West Bank and Gaza Strip, Yemen 
WHO European 
Region 
EUR High-income Andorra, Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, 
Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, 
Portugal, Russian Federation, Slovakia, Slovenia, Spain, Sweden, 
Switzerland, United Kingdom 
  Low- or middle-income Albania, Armenia, Azerbaijan, Belarus, Bosnia Herzegovina, Bulgaria, 
Georgia, Hungary, Kazakhstan, Kyrgyzstan, Republic of Moldova, Romania, 
Serbia, Tajikistan, Turkey, Turkmenistan, Ukraine, Uzbekistan 
WHO Southeast 
Asian Region 
SEAR High-income None 
  Low- or middle-income Bangladesh, Indonesia, India, Sri Lanka, Maldives, Myanmar, Nepal, 
Thailand, Timor-Leste 
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Table 3: WHO region descriptions (continued) 
WHO region Acronym Income category Countries with model results 
WHO Western 
Pacific Region 
WPR High-income Australia, Brunei Darussalam, Japan, Republic of Korea, New Zealand, 
Singapore 
  Low- or middle-income Cambodia, China, Cook Islands, Fiji, Kiribati, Lao People's Dem. Rep., 
Malaysia, Marshall Islands, Mongolia, Nauru, Niue, Palau, Papua New 
Guinea, Philippines, Samoa, Solomon Islands, Tonga, Tuvalu, Vanuatu, Viet 
Nam 
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2.4.9. Model selection 
Comparison between models with and without an interaction between time and period was 
conducted using the Bayesian information criterion (BIC). Given a set of candidate models, 
selection of the model with the lowest BIC is equivalent to choosing the model with the 
highest posterior probability—that is, the most plausible model given the dataset. The BIC 
approximates a transformation of the posterior probability while incorporating a penalty 
against overfitting as shown in Equation 7. !"# = −2 ln ! + ! ln!  (7) 
Where ! is the maximized likelihood of the model, k is the number of parameters to be 
estimated and n is the sample size. In practice, a BIC less than six provides no strong 
evidence of a difference between candidate models [123-125]. 
2.4.10. Model diagnostics 
Models were assessed for convergence, predictive accuracy and robustness. Formal 
convergence diagnostics were conducted using Gelman-Rubin statistics [126]. Predictive 
accuracy tests involved calculation of root-mean-squared-errors (RMSEs) and coverage of 
95% posterior predictive intervals. Checks for robustness in out-of-sample prediction were 
conducted via hold-out cross-validation.  
 
The Gelman-Rubin diagnostic assesses convergence by comparing multiple sets of iterations 
(“chains”) of MCMC simulations. If the chains have reached acceptable approximations of 
the posterior distributions of the parameters of interest, then they should be very similar to 
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one another. This similarity is quantified through the potential scale reduction measure (!) 
given in Equation 8. ! = !"#(!|!)!  (8) 
 !"#(!|!) is an estimate of the marginal posterior variance of the parameter θ given in 
Equation 9. !"# ! ! = !!!! ! + !!!  (9) 
 
Where n is the number of iterations, W is the within-chain variance and B is the 
between-chain variance given in Equations 10 and 11 respectively. ! = !! !!!! !!" − !.! !!!!!!!!!  (10) ! = !!!! (!.! − !..)!!!!!   (11) 
Where m is the number of chains. In practice, values of ! close to one mean that lack of 
convergence was not detected [126, 127]. 
 
Predictive accuracy checks were conducted for each country-sex model using RMSEs and 
coverage of 95% posterior predictive intervals for individual age-sex-country-year specific 
datapoints. Cross-validation was conducted by holding-out datapoints for the years 2005 or 
later starting from the first-stage regional fits until the final country fits. The training dataset 
on which models were fitted consisted of datapoints from 1990 to 2004 and the test dataset 
against which model predictions were compared consisted of datapoints from 2005 onwards. 
Low RMSEs and high coverage values mean more accurate predictions in comparison with 
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observed data. Small differences in RMSE and coverage between different datasets show 
robustness of estimates to dataset changes. Low RMSEs and high coverage test dataset 
results mean more accurate projections.  
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3. RESULTS 
Models could be built and results obtained for 173 countries for men and 178 countries for 
women. Model estimates could not be obtained for a few country-sex groups because some 
countries have data only for one of the sexes. Generally, there are more countries with 
available data for women because of investments in multi-country survey programs which 
assess women’s reproductive and maternal health and include health risks such as smoking. 
This section presents results for model selection, tobacco use trends and projections and 
model diagnostics. 
3.1. Model selection 
Country- and sex-specific estimates of smoking prevalence from 1990 to 2010 were best 
estimated by a model that included an interaction between time and period, indicating a 
change in trends in smoking at the turn of the century. Models—by country and sex—with 
and without an interaction term between the time and period variables were compared using 
the BIC [125]. For men, the average change in BIC was 4.3 and ΔBIC values ranged from 0.6 
to 117.5. For women, the average change in BIC was 3.9 and ΔBIC values ranged from 0 to 
45.4. Summaries of the model comparisons for men and for women are provided in Figure 2 
and Figure 3 respectively.  
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Figure 2: Change in BIC between models with and without interaction terms for men 
 
 
Figure 3: Change in BIC between models with and without interactions terms for women 
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Given that the vast majority of country-sex models—95% for men and 94% for women—had 
no strong evidence (ΔBIC <6) [125] against the inclusion of an interaction term, and 
accounting for the epidemiologic plausibility of a slope change in time trends, the model with 
an interaction between time and period was selected, and all results in the remainder of this 
chapter are derived from this model. 
 
3.2. Tobacco use trends and projections 
Results were obtained for 173 countries for men and 178 countries for women. This section 
focuses on current tobacco smoking, which encompasses occasional and daily smoking for 
all smoked tobacco product types and is the most important indicator of tobacco use globally 
[83]. Country-specific estimates of current tobacco smoking prevalence in 2000, 2010 and 
2025 are provided in Appendix C. Country-specific estimates of relative percentage changes 
and posterior probabilities of reduction, increase and target achievement for current tobacco 
smoking are provided as Appendix D. Country-specific estimates of prevalence in 2010 and 
2025 for the three other indicators—daily tobacco smoking, current cigarette smoking, daily 
cigarette smoking—are included in the WHO global report on trends in prevalence of 
tobacco smoking [113]. 
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3.2.1. Recent global prevalence estimates and projections to 2025 
Quintiles of mean prevalence by sex were obtained for 2000, 2010 and for 2025. The first 
quintile is comprised of countries with the lowest prevalences, while the fifth quintile 
contains countries with the highest prevalences. Prevalence estimates in 2000 ranged from 
less than 25% in the first quintile to 56% or greater in the fifth quintile for men, and from less 
than 3% in the first quintile to 27% or greater in the fifth quintile for women. For men, 21 
countries (57%) in the first quintile were low- or middle-income (LMI) countries in Africa 
and the fifth quintile was concentrated in Europe and the Western Pacific. For women, the 
first quintile was comprised mostly (84%) of 26 LMI countries from diverse geographies 
including 14 (45%) African nations. Conversely, countries in the fifth quintile were 
concentrated mainly in Europe and the Western Pacific. By 2010, estimated prevalences 
ranged from less than 24% in the first quintile to 48% or greater in the fifth quintile for men, 
and from less than 2% in the first quintile to 22% or greater in the fifth quintile for women. 
For men, 24 of the first quintile (67%) were LMI countries in Africa and the Americas with 
several African nations increasing in prevalence. The composition of the fifth quintile 
remained similar to 2000. For women, patterns in the first and the fifth quintiles also 
remained similar to 2000. Prevalence quintiles in 2010 by WHO region and World Bank 
income categories are provided in Table 4 for men and Table 5 for women. 
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Table 4: Prevalence quintiles in 2010 by WHO region and World Bank income category for 
men 
 
Mean prevalence, 2010, % 
 <24 24 to <31 31 to <40 40 to <48 ≥48 
Region 
Countries Region 
total N† N† %‡ N† %‡ N† %‡ N† %‡ N† %‡ 
Low- or middle-income 
AFR 40 14 35  9 23  12 30  4 10  1 3  40  
AMR 23 10 32  4 13  5 16  2 6  2 6  31  
EMR 13 0 0  2 11  0 0  6 32  5 26  19  
EUR 17 1 2  1 2  1 2  6 13  8 17  48  
SEAR 9 0 0  2 22  2 22  3 33  2 22  9  
WPR 20 1 4  0 0  1 4  8 31  10 38  26  
Subtotal 122 26 21  18 15  21 17  29 24  28 23   
             
High-income 
AFR 0 0 0  0 0  0 0  0 0  0 0  40  
AMR 8 4 13  1 3  1 3  2 6  0 0  31  
EMR 6 1 5  3 16  1 5  1 5  0 0  19  
EUR 31 3 6  8 17  12 25  4 8  4 8  48  
SEAR 0 0 0  0 0  0 0  0 0  0 0  9  
WPR 6 2 8  2 8  0 0  1 4  1 4  26  
Subtotal 51 10 20  14 27  14 27  8 16  5 10   
             
TOTAL 173 36 21  32 21  35 21  37 21  33 21  173 
†number of countries 
‡proportion of the regional population 
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Table 5: Prevalence quintiles in 2010 by WHO region and World Bank income category for 
women 
 
Mean prevalence, 2010, % 
 <2 2 to <4 4 to <11 11 to <22 ≥22 
Region 
Countries Region 
total N† N† %‡ N† %‡ N† %‡ N† %‡ N† %‡ 
Low- or middle-income 
AFR 42 15 36  15 36  10 24  2 5  0 0  42  
AMR 25 2 6  7 21  10 30  4 12  2 6  33  
EMR 13 4 21  4 21  2 11  2 11  1 5  19  
EUR 18 5 10  1 2  4 8  3 6  5 10  49  
SEAR 9 2 22  4 44  2 22  1 11  0 0  9  
WPR 20 3 12  1 4  3 12  6 23  7 27  26  
Subtotal 127 31 24  32 25  31 24  18 14  15 12   
             
High-income 
AFR 0 0 0  0 0  0 0  0 0  0 0  42  
AMR 8 2 6  1 3  1 3  2 6  2 6  33  
EMR 6 2 11  2 11  2 11  0 0  0 0  19  
EUR 31 0 0  0 0  0 0  14 29  17 35  49  
SEAR 0 0 0  0 0  0 0  0 0  0 0  9  
WPR 6 0 0  1 4  2 8  3 12  0 0  26  
Subtotal 51 4 8  4 8  5 10  19 37  19 37   
             
TOTAL 178 35 20  36 20  36 20  37 21  34 19  178 
†number of countries 
‡proportion of the regional population 
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If recent trends remain unchanged, the global distribution of projected prevalence in 2025 
will be as shown in Figure 4 for men and in Figure 5 for women. Such tobacco use patterns 
translate to an estimated 1.1 billion current smokers (700 million—1.6 billion) in 2025.
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Figure 4: Estimated mean 15+ age-standardized current tobacco smoking prevalence in 2025 for men 
Current smokers, Men
Prevalence quintiles, 2025, %
<20 20 to <29 29 to <36 36 to <49 >49
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Figure 5: Estimated mean 15+ age-standardized current tobacco smoking prevalence in 2025 for women 
Current smokers, Women
Prevalence quintiles, 2025, %
<1 1 to <3 3 to <8 8 to <18 >18
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Prevalence quintiles in 2025 by WHO region and World Bank income categories are 
provided in Table 6 for men and Table 7 for women. It is projected that the highest smoking 
quintile among men will shift from LMI countries in Europe and the Western Pacific to those 
in Africa and the Eastern Mediterranean, indicating a rapidly growing epidemic of tobacco 
smoking in this region and a major additional burden of non-communicable disease in these 
countries. For women, 2025 prevalence patterns will remain similar to baseline with the first 
quintile comprised mostly of LMI settings from diverse geographies including 12 African 
nations (34%), and the fifth quintile concentrated in Europe and the Western Pacific. 
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Table 6: Prevalence quintiles in 2025 by WHO region and World Bank income category for 
men 
 
Mean prevalence, 2025, % 
 <20 20 to <29 29 to <36 36 to <49 ≥49 
Region 
Countries Region 
total N† N† %‡ N† %‡ N† %‡ N† %‡ N† %‡ 
Low- or middle-income 
AFR 40 6 15  11 28  6 15  6 15  11 28  40  
AMR 23 11 35  6 19  4 13  1 3  1 3  31  
EMR 13 1 5  1 5  0 0  1 5  10 53  19  
EUR 17 1 2  2 4  4 8  7 15  3 6  48  
SEAR 9 1 11  1 11  4 44  1 11  2 22  9  
WPR 20 1 4  1 4  4 15  12 46  2 8  26  
Subtotal 122 21 17  22 18  22 18  28 23  29 24   
             
High-income 
AFR 0 0 0  0 0  0 0  0 0  0 0  40  
AMR 8 5 16  1 3  1 3  1 3  0 0  31  
EMR 6 0 0  0 0  2 11  0 0  4 21  19  
EUR 31 6 13  13 27  6 13  5 10  1 2  48  
SEAR 0 0 0  0 0  0 0  0 0  0 0  9  
WPR 6 2 8  1 4  2 8  0 0  1 4  26  
Subtotal 51 13 25  15 29  11 22  6 12  6 12   
             
TOTAL 173 34 20  37 21  33 19  34 20  35 20  173 
†number of countries 
‡proportion of the regional population 
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Table 7: Prevalence quintiles in 2025 by WHO region and World Bank income category for 
women 
 
Mean prevalence, 2025, % 
 <1 1 to <3 3 to <8 8 to <18 ≥18 
Region 
Countries Region 
total N† N† %‡ N† %‡ N† %‡ N† %‡ N† %‡ 
Low- or middle-income 
AFR 42 12 29  17 40  11 26  2 5  0 0  42  
AMR 25 3 9  8 24  9 27  5 15  0 0  33  
EMR 13 5 26  2 11  1 5  2 11  3 16  19  
EUR 18 5 10  1 2  3 6  4 8  5 10  49  
SEAR 9 4 44  3 33  2 22  0 0  0 0  9  
WPR 20 3 12  1 4  4 15  5 19  7 27  26  
Subtotal 127 32 25  32 25  30 24  18 14  15 12   
             
High-income 
AFR 0 0 0  0 0  0 0  0 0  0 0  42  
AMR 8 2 6  1 3  2 6  2 6  1 3  33  
EMR 6 1 5  2 11  2 11  1 5  0 0  19  
EUR 31 0 0  0 0  0 0  11 22  20 41  49  
SEAR 0 0 0  0 0  0 0  0 0  0 0  9  
WPR 6 0 0  1 4  2 8  3 12  0 0  26  
Subtotal 51 3 6  4 8  6 12  17 33  21 41   
             
TOTAL 178 35 20  36 20  36 20  35 20  36 20  178 
†number of countries 
‡proportion of the regional population 
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3.2.2. Recent and future trajectories and prevalence changes 
From 2000 to 2010, 125 countries experienced declines in prevalence for men (72%), and 
155 countries (87%) for women, showing that tobacco control efforts have been successful. 
Even if such trends continue however, only 43 countries (25%) for men and 93 (52%) for 
women will have ≥95% probability of decline from 2010 to 2025, and 21 countries (12%) 
will have ≥95% probability of increase among men over the same period. Patterns in trend 
estimates from 2000 to 2010 and probabilities of reduction and increase in prevalence from 
2010 to 2025 by region and income category are summarized in Table 8 for men and Table 9 
for women. High (≥95%) probabilities of decline were found for the majority of countries in 
the Americas for both men and women. In contrast, high probabilities of increase were 
estimated for about a third of countries in Africa and the Eastern Mediterranean for men. For 
European men, 15 high-income countries (48%) had a high probability of reduction, 
compared to only four low- or middle-income countries (24%), indicating that within-region 
income inequalities remain an issue in tobacco control. 
 
Maps of relative percentage changes from 2010 to 2025 are provided in Figure 6 for men and 
in Figure 7 for women. Declines are projected for the majority of countries in almost all 
regions except Africa for men and the Eastern Mediterranean for both men and women. 
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Table 8: Relative change in 15+ age-standardized current tobacco smoking prevalence by 
WHO region and World Bank income category for men 
Region Countries Direction of trend, 2000-2010 ≥95% probability, 2010-2025 
Decrease Increase Decrease Increase 
Number 
(N) N 
 % popa 
covered  N 
% popa 
covered N 
% popa 
covered N 
% popa 
covered 
Low- or middle-income 
AFR 40 15  44  25  56  1 5  15 37  
AMR 23 22  57  1  1  13 54  0 0  
EMR 13 2  14  11  73  0 0  2 2  
EUR 17 16  27  1  <1  4 12  0 0  
SEAR 9 7  86  2  14  3 80  0 0  
WPR 20 20  89  0  0  1 5  0 0  
Subtotal 122 82 80  40 20  22 40  17 5  
          
High-income 
AFR 0 0 0  0 0  0 0  0 0  
AMR 8 7 42  1 <1  3 39  0 0  
EMR 6 0 0  6 13  0 0  4 5  
EUR 31 31 73  0 0  15 25  0 0  
SEAR 0 0 0  0 0  0 0  0 0  
WPR 6 5 11  1 <1  3 8  0 0  
Subtotal 51 43 94  8 6  21 56  4 2  
          
TOTAL 173 125 83 48 17 43 43 21 5 
a% pop covered refers to the proportion of the regional population 
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Table 9: Relative change in 15+ age-standardized current tobacco smoking prevalence by 
WHO region and World Bank income category for women 
Region Countries Direction of trend, 2000-2010 ≥95% probability, 2010-2025 
Decrease Increase Decrease Increase 
Number 
(N) N 
 % popa 
covered  N 
% popa 
covered N 
% popa 
covered N 
% popa 
covered 
Low- or middle-income 
AFR 42 36  88  6  12  21 50  0 0  
AMR 25 25  60  0  0  24 60  0 0  
EMR 13 7  74  6  18  6 74  0 0  
EUR 18 16  27  2  1  6 11  0 0  
SEAR 9 9  100  0  0  9 100  0 0  
WPR 20 20  88  0  0  7 87  0 0  
Subtotal 127 113 96  14 4  73 88  0 0  
          
High-income 
AFR 0 0 0  0 0  0 0 0 0  
AMR 8 8 40  0 0  7 38  0 0  
EMR 6 1 4  5 3  0  0 0 0  
EUR 31 27 56  4 16  9 16  0 0  
SEAR 0 0 0  0 0  0 0  0 0  
WPR 6 6 12  0 0  4 9  0 0  
Subtotal 51 42 88  9 12  20 51  0 0  
          
TOTAL 178 155 95 23 5 93 81 0 0 
a% pop covered refers to the proportion of the regional population 
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Figure 6: Relative change in 15+ age-satndardized current tobacco smoking prevalence between 2010 and 2025 for men 
Current smokers, Men
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Figure 7: Relative change in 15+ age-standardized current tobacco smoking prevalence between 2010 and 2025 for women
Current smokers, Women
−88 −47 −40 −35.1 −23 −16 −4.57 72
Relative change in prevalence, 2010 − 2025, %
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3.2.3. Target achievement assessment and probabilities 
Scatterplots of relative percentage changes from 2010 to 2025 against baseline prevalence in 
2010 with countries categorized according to probabilities of achieving the 30% relative 
reduction in tobacco use target are provided in Figure 8 for men and in Figure 9 for women. 
Only 37 countries (21%) are on track to achieve their targets for men and 88 (49%) for 
women. Only three countries for men (2%) and 22 for women (12%) had high probabilities 
(≥95%) of target achievement. Relative prevalence increases of more than 100% 
accompanied by low (<5%) probabilities of target achievement were estimated for men in 
seven countries (4%) in Africa and the Eastern Mediterranean.  
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Figure 8: Relative change in 15+ age-standardized current tobacco smoking prevalence  
versus baseline prevalence and target achievement probabilities for men 
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Figure 9: Relative change in mean 15+ age-standardized current tobacco smoking prevalence 2010-2025  
versus baseline prevalence and target achievement probabilities for women
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Target achievement probabilities are mapped in Figure 10 for men and in Figure 11 for 
women. Low (<5%) target achievement probabilities were found in a number of countries for 
both sexes with several in Africa and the Eastern Mediterranean for men and in Europe for 
women. 
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Figure 10: Map of probability of achieving 30% reduction in current tobacco smoking prevalence by 2025 
Current smokers, Men
Probability of achieving target
>=95% 50 to <95% 5 to <50% <5%
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Figure 11: Map of probability of achieving 30% reduction in current tobacco smoking prevalence by 2025 
Current smokers, Women
Probability of achieving target
>=95% 50 to <95% 5 to <50% <5%
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Summaries of target achievement and corresponding probabilities by WHO region and World 
Bank income classification are given in Table 10 for men and in Table 11 for women. For 
men, low- and middle-income settings had a higher proportion (31%) of countries with low 
(<5%) target achievement probabilities compared to high-income settings (16%). Conversely 
for women, high-income settings had a higher proportion (24%) of countries with low target 
achievement probabilities compared to low- and middle-income settings (9%). These suggest 
continued growth of tobacco smoking among men in low-income countries and persistence of 
the smoking epidemic among women in high-income countries. 
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Table 10: Probability of achieving 30% reduction in tobacco use target by WHO region and 
World Bank income category for men 
Region Countries Target 
achievement 
Probability of achieving target 
<5% 5 - <50% 50 - <95% ≥95% 
Number 
(N) 
N 
% reg 
popa  
N 
% reg 
popa 
N 
% reg 
popa 
N 
% reg 
popa 
N 
% reg 
popa 
Low- or middle-income 
AFR 40 1 5 24 51 15 44 1 5 0 0 
AMR 23 16 55 1 1 6 3 15 54 1 <1 
EMR 13 0 0 9 70 4 3 0 0 0 0 
EUR 17 2 9 2 <1 12 15 3 12 0 0 
SEAR 9 3 80 2 17 4 17 3 80 0 0 
WPR 20 2 <1 0 0 18 89 2 <1 0 0 
Subtotal 122 24 38 38 20 59 42 24 38 1 <1 
            
High-income 
AFR 0 0 0 0 0 0 0 0 0 0 0 
AMR 8 2 4 0 0 5 2 3 39 0 0 
EMR 6 0 0 6 13 0 0 0 0 0 0 
EUR 31 8 16 1 <1 21 55 7 17 2 1 
SEAR 0 0 0 0 0 0 0 0 0 0 0 
WPR 6 3 8 1 <1 2 3 3 8 0 0 
Subtotal 51 13 25 8 6 28 43 13 50 2 <1 
            
TOTAL 173 37 35 46 17 87 42 37 40 3 <1 
a% reg pop refers to the proportion of the regional population 
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Table 11: Probability of achieving 30% reduction in tobacco use target by WHO region and 
World Bank income category for women 
Region Countries Target 
achievement 
Probability of achieving target 
<5% 5 - <50% 50 - <95% ≥95% 
Number 
(N) 
N 
% reg 
popa  
N 
% reg 
popa 
N 
% reg 
popa 
N 
% reg 
popa 
N 
% reg 
popa 
Low- or middle-income 
AFR 42 22 50 4 9 15 36 21 50 2 5 
AMR 25 25 60 0 0 0 0 24 48 1 13 
EMR 13 6 74 6 18 1 <1 0 0 6 74 
EUR 18 5 10 2 1 11 16 5 10 0 0 
SEAR 9 8 96 0 0 1 4 2 14 6 82 
WPR 20 6 82 0 0 13 <1 5 86 2 1 
Subtotal 127 72 85 12 3 41 10 57 51 17 36 
            
High-income 
AFR 0 0 0 0 0 0 0 0 0 0 0 
AMR 8 7 38 0 0 1 2 5 34 2 4 
EMR 6 0 0 4 3 2 5 0 0 0 0 
EUR 31 6 13 8 32 16 26 5 12 2 1 
SEAR 0 0 0 0 0 0 0 0 0 0 0 
WPR 6 3 2 0 0 3 10 2 1 1 <1 
Subtotal 51 16 40 12 24 22 36 12 36 5 4 
            
TOTAL 178 88 76 24 7 63 15 69 48 22 30 
a% reg pop refers to the proportion of the regional population 
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3.3. Model diagnostics 
This section presents results of assessments for convergence, predictive accuracy and 
robustness. 
3.3.1. Formal convergence checks 
Summaries of the Gelman-Rubin statistic for parameters of models by country and sex are 
provided in Table 12 for men and Table 13 for women. 
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Table 12: Summary of Gelman-Rubin statistics for country-sex model parameters for men 
Parameter Summary measure 
(Number of countries = 173) 
Mean Standard deviation 
βtime 1.006 0.009 
βperiod 1.007 0.012 
βtimexperiod 1.007 0.010 
βsmkd 1.008 0.011 
βcigc 1.010 0.018 
βcigd 1.007 0.012 
η 1.003 0.006 
γ15 1.007 0.012 
γ20 1.008 0.012 
γ30 1.009 0.015 
γ40 1.009 0.013 
γ50 1.009 0.015 
γ60 1.008 0.014 
γ70 1.008 0.013 
γ80 1.007 0.012 
γ100 1.006 0.011 
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Table 13: Summary of Gelman-Rubin statistics for country-sex model parameters for women 
Parameter Summary measure 
(Number of countries = 178) 
Mean Standard deviation 
βtime 1.008 0.014 
βperiod 1.007 0.012 
βtimexperiod 1.006 0.010 
βsmkd 1.008 0.013 
βcigc 1.011 0.039 
βcigd 1.007 0.011 
η 1.003 0.009 
γ15 1.009 0.026 
γ20 1.009 0.026 
γ30 1.010 0.032 
γ40 1.011 0.039 
γ50 1.012 0.053 
γ60 1.014 0.072 
γ70 1.016 0.087 
γ80 1.015 0.088 
γ100 1.010 0.040 
 
Given that the values of the Gelman-Rubin statistic for each parameter are generally close to 
one [127], there was no lack of convergence detected. 
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3.3.2. Predictive accuracy and robustness checks 
Summaries of predictive accuracy checks and cross-validation results are provided in Table 
14, Figure 12, Figure 13, Figure 14 and Figure 15. In Table 14, the full dataset is comprised 
of all datapoints included in this analysis from 1990 to 2014, the training dataset contains 
datapoints from 1990 to 2004, and the test dataset is composed of datapoints from 2005 
onwards. Cross-validation could only be conducted for a subset of countries in the analysis 
due to data limitations. 
 
Table 14: Summary of predictive validity results 
Measure Dataset Summary statistics 
No. of 
countries 
Mean SD Min Median Max 
Men 
RMSE Full 173 .065 .028 .021 .058 .185 
 Training 111 .091 .106 .019 .068 .944 
 Test 111 .118 .078 .031 .101 .662 
Coverage Full 173 .994 .014 .938 1.000 1.000 
 Training 111 .996 .012 .944 1.000 1.000 
 Test 111 .925 .147 .125 1.000 1.000 
Women 
RMSE Full 178 .031 .024 .001 .024 .111 
 Training 115 .043 .033 .001 .037 .187 
 Test 115 .072 .095 .001 .050 .702 
Coverage Full 178 .985 .023 .893 1.000 1.000 
 Training 115 .988 .026 .889 1.000 1.000 
 Test 115 .861 .198 .000 .941 1.000 
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In general, small RMSEs and high coverage values indicate that the models estimate 
accurately, and predicted values lie close to the observed data. RMSE always increases in the 
test dataset compared to the full or training datasets, indicating the challenges of 
out-of-sample prediction, but the RMSEs in the test dataset remain low. Low RMSEs and 
high coverage in comparison in the test dataset mean the models are not overfitted, retain 
accuracy in out-of-sample prediction, and are suitable for projection. 
 
Distributions of the coverage of posterior predictive intervals of individual country-sex 
models fitted using the full dataset are shown in Figure 12 for men and Figure 13 for women 
respectively.  
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Figure 12: Coverage of posterior predictive intervals for country-sex models for men 
 
 
Figure 13: Coverage of posterior predictive intervals for country-sex models for women 
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The vast majority of countries have high coverage of posterior predictive intervals for men 
and for women, indicating that predicted values from most country-sex models lie close to 
the observed data. 
 
Distributions of the RMSEs of individual country-sex models fitted using full datasets are 
shown in Figure 14 for men and Figure 15 for women respectively. 
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Figure 14: RMSEs for country-sex models for men 
 
 
Figure 15: RMSEs for country-sex models for women 
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The majority of countries have small RMSEs relative to the magnitude of prevalence values 
in the dataset for men and for women. Generally, there was no substantial difference in 
predictive ability between the country-sex models for men and those for women. Although 
RMSEs were generally larger for country-sex models for men relative to those for women, 
RMSEs were calculated in the same scale as prevalence values and not normalized, thus, the 
apparent discrepancy in accuracy could be attributed to the higher magnitude of observed 
prevalences among men relative to women. Coverage of posterior predictive intervals was 
≥95% for the vast majority of country-sex models for men (97%) and for women (94%) 
indicating that model predictions generally lie close to the observed values and adequately 
account for sampling variability for both sexes. 
 
Overall, diagnostics for convergence, predictive accuracy and robustness demonstrated that 
the models perform well for the vast majority of countries for both sexes. 
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4. DISCUSSION 
This study provides the most comprehensive set of comparable and consistent estimates and 
projections for four tobacco use indicators and for target achievement under the WHO global 
monitoring framework. It uses the most up-to-date dataset and a comprehensive modeling 
process that enables information from multiple indicators to be used directly in a single 
flexible model. Tobacco smoking prevalence trends were estimated from 1990 to 2010 using 
data available until 2014, with projections to 2025 for 178 countries. Relative percentage 
changes in prevalence in the most recent decade (2000-2010) and between 2010 and 2025 
were estimated. Posterior probabilities of reduction, increase and target achievement for the 
2010-2025 period were obtained. National authorities were engaged to ensure a 
comprehensive database, the latest available survey data were used, and consultation with 
individual countries regarding discrepancies was conducted as part of the WHO global 
estimation process. 
 
During the most recent decade (2000–2010), the prevalence of tobacco smoking in men fell 
in 125 countries (72%), and in women fell in 155 countries (87%). Even if such global 
declines continue however, only 37 (21%) countries are on track to achieve their targets for 
men and 88 (49%) are on track for women. These translate to more than one billion current 
tobacco smokers in 2025 due to population growth. If such trends remain unchanged, striking 
country disparities would persist and rapid increases are predicted in Africa for men and in 
the eastern Mediterranean for both men and women. 
  84 
4.1. Global prevalence and control strategies 
There was wide variation in baseline prevalence, reflective of differences in tobacco 
epidemic stages and in control efforts between countries. Prevalence projections suggest that 
such disparities are likely to persist. Countries already at mature stages of the smoking 
epidemic at baseline and which are projected to retain high prevalence in 2025 require 
immediate and effective implementation or strengthening of measures for inducing cessation, 
avoiding relapse and deterring further initiation. These could include Indonesia for example, 
which is in the highest quintile in 2010 at >65% prevalence for men and is projected to retain 
high prevalence in 2025 with a >90% probability of increase. In Indonesia at present, 
cessation services are not publicly-funded, the tobacco industry enjoys considerable 
marketing freedom, tobacco taxation is only at 51% and smoke-free legislation does not 
cover all types of public places [48]. Improvement of such weak tobacco control policies 
could help curb the nation’s immense smoking problem. Countries where the smoking 
epidemic has not gained a foothold or is in its early stages are mostly in LMI settings where 
tobacco control may not currently be prioritized due to limited resources for addressing 
pressing health concerns. However, such situations present opportunities for these countries’ 
governments, in cooperation with the international community, to invest in or strengthen 
cost-effective prevention strategies before tobacco companies establish and expand their 
markets. Togo for instance has low smoking prevalence for both men (14%) and women 
(2%) at baseline. However, demand-reduction measures other than health warnings are 
severely lacking [48] and the country is also experiencing threats of expensive litigation from 
Philip Morris International. However, if Togo makes the most of global tobacco control 
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initiatives such as the Anti-Tobacco Trade Litigation Fund, [51] then pre-emptive action 
against a smoking epidemic could be taken.  
4.2. Trajectories and socioeconomic tobacco control factors 
Global, regional and intra-regional patterns in country trajectories identified in this study 
reflect patterns in tobacco control efforts. This study found downward trajectories in 
prevalence in 72% (125) of countries for men and in 87% (155) of countries for women. This 
is consistent with the findings of other analyses [53, 103] as a consequence of growing 
tobacco control efforts over the past two decades [48]. Regional patterns were observed, such 
as high (≥95%) probabilities of reduction estimated for the majority of countries in the 
Americas. These included 52% (16) of countries for men and 94% (31) of countries for 
women involving a mix of high- and low- or middle-income economies such as the United 
States and Mexico respectively. Lessons could be taken from these countries with success 
stories. The success of tobacco control in the United States, evidenced by a ratio of former to 
current smokers in middle age greater than one [128], shows the value of sustained state-level 
funding for model comprehensive tobacco control programs that have been running since the 
early 1990s [129]. Mexico’s success is backed by an estimated reduction in smoking 
prevalence of more than 50% over three decades and by strong civil society support for 
implementation of tobacco control policies [53, 130]. This study’s findings are also consistent 
with significant progress in smoke-free policy implementation among several LMI Latin 
American countries after FCTC ratification in the region and are suggestive of the potential to 
build regional momentum in tobacco control [131]. Within-region disparities were also found 
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however, such as greater proportions of high-income (15 or 48%) relative to low- or 
middle-income countries (4 or 24%) with high (≥95%) estimated probabilities of reduction 
for European men. To prevent widening tobacco-related regional health inequalities, sharing 
of best practices by model countries, intraregional assistance and comprehensive regional 
tobacco control strategies should undergo immediate and effective implementation. 
4.3. Target achievement and MPOWER implementation 
This study found that 136 countries (79%) for men and 90 countries (51%) for women will 
not achieve the 30% reduction target if current trends remain unchanged, and more effort is 
required to attain or to maintain desirable trajectories. For this, the WHO MPOWER [13, 
105] tobacco control policy package serves as a good starting point. Aimed at assisting 
country-level FCTC implementation, it consists of six components: “monitor tobacco use and 
prevention policies, protect people from tobacco smoke, offer help to quit tobacco use, warn 
about the dangers of tobacco, enforce bans on tobacco advertising, promotion and 
sponsorship, and raise taxes on tobacco” [13]. Although the FCTC has been ratified by 180 
countries to date [132], completeness of implementation of MPOWER measures, and 
compliance with MPOWER standards, varies greatly across countries [48]. The importance 
of immediate and extensive MPOWER implementation is exemplified by Uruguay, which we 
project will achieve a greater than 40% reduction in current smoking prevalence, representing 
an annual 2.7% decrease over 15 years, with high probabilities of reduction (≥95%) for both 
men and women. After FCTC ratification in 2004 and initiation of FCTC-based measures in 
2005, Uruguay achieved high levels of MPOWER implementation and an estimated annual 
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rate of decrease greater than 3% in tobacco use prevalence over the period 2005 to 2011 even 
though it had no significant reductions in tobacco use before 2005 [133]. If sustained, such a 
declining trend would be sufficient to attain the 2% annual reduction over 15 years required 
by the target. Even countries on track towards target achievement should be vigilant however, 
and exert efforts to maintain desirable trajectories. Norway provides an example of the 
importance of vigilance in maintaining tobacco control efforts. This study estimated that 
Norway will achieve a 45% reduction in current smoking prevalence, representing a 3% 
annual decrease over 15 years with high probabilities (>95%) for both men and women. After 
waning tobacco control prioritization in the 1980s and stalled prevalence reductions, tobacco 
use reductions were again achieved after reinvigoration of the national tobacco control 
program in the 1990s, and have been maintained [134]. Norway was able to achieve 30% 
tobacco use reduction within a decade [135] and its national tobacco control strategy 
continues to evolve [136]. These countries offer lessons in effective tobacco control, and 
show the potential value of the MPOWER package for countries that we have identified are 
at risk of increasing or static trends in current smoking prevalence. 
4.4. Contextual tobacco use factors 
While tobacco control strategies are at the forefront of changes in tobacco use prevalence, 
smoking trends may also be reflective of other factors. Similar to Norway, Sweden is 
projected to achieve ≥37% relative reduction in current smoking prevalence, representing 
annual decreases over 15 years for both men and women of approximately 2.4%. In both 
countries however, consumption of a smokeless oral form of tobacco called snus has been 
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increasing in recent years [137-139]. While it is suggested that use of snus may be helpful in 
smoking cessation, its health effects remain controversial and debate about its role as a 
tobacco cessation strategy is ongoing [138, 140, 141]. Some portion of Norway and Sweden’s 
success may therefore represent substitution to unmeasured forms rather than cessation, and 
for any country the particular cultural context of tobacco use remains an important 
consideration in interpreting the model outputs. This also holds for developing countries such 
as India and Myanmar, which are both projected to achieve the target for tobacco smoking for 
men and for women. However, smokeless tobacco use is prevalent (≥20%) in both countries 
and due to gaps in knowledge [55, 142], it is unclear how the trend for smokeless use would 
compare with the smoking trajectories for these nations. 
4.5. Vulnerable populations requiring attention and action 
Patterns in target achievement probabilities, trajectories and projected prevalence reveal areas 
for attention. Low target achievement probabilities and upward trends in prevalence were 
estimated for the majority of countries in the WHO African Region (AFR) for men and in the 
WHO Eastern Mediterranean Region (EMR) for both sexes. For men, both regions have a 
number of countries—6 (32%) for EMR and 15 (38%) for AFR—with high (≥95%) 
estimated probabilities of increase, and 37% of the population covered by the AFR region is 
almost certain to experience increases in tobacco smoking by 2025 if urgent action is not 
taken to reverse the progress of the smoking epidemic. Global inequalities in tobacco control 
continue to exist and international cooperation is thus called for, consistent with evidence that 
country capacity is a crucial mediator in tobacco control measure implementation [143]. 
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Given increasing trends in other NCD risk factors such as blood pressure [144] and high body 
mass index [145], and low resources for several countries in these regions, immediate and 
effective action must be taken to prevent potential NCD epidemics that could burden already 
fragile health systems. Tobacco is the most policy-responsive NCD risk factor [103] and with 
price the key determinant of initiation and cessation, high specific excise taxes on all brands 
could prevent increases and induce reductions in prevalence as well as generate revenues for 
health financing [128] for these countries. 
4.6. More ambitious and context-specific targets 
Synthesis of target achievement probabilities and projected prevalence also provide impetus 
for stronger tobacco control strategies even for high-income countries. Projected target 
achievement must not be taken as cause for complacency as some countries like Japan with 
>50% probability of achieving the target would still belong to the third highest quintile of 
current tobacco smoking prevalence (29 to <36%) among men in 2025. These findings lend 
support to a modeling exercise that recommended a more ambitious tobacco use reduction 
target in order to achieve corresponding goals in reducing premature NCD mortality [103]. 
While a 30% relative reduction is feasible based on previous experience and is useful for 
benchmarking progress [5], it should not hold countries back from aspiring to more 
challenging yet efficient pathways towards tobacco use elimination. Recently, global tobacco 
control experts have proposed a goal of less than 5% tobacco use prevalence among adults 
worldwide to be achieved by 2040 and have made a call to accomplish this target by 
phasing-out tobacco sales globally [146]. Regardless of their likelihood of achieving their 
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30% reduction target, national governments should consider further scaling up of tobacco 
control efforts to aim for this stricter absolute goal. 
 
While global targets are relevant for political attention and commitment, public awareness, 
and advocacy, such goals may not be applicable in some situations. As this study found for 
women in Benin and Burundi in Africa, a 30% relative reduction may be unachievable for 
certain countries simply due to the difficulty in tackling very low baseline prevalences. In 
such cases, a separate national absolute reduction target or conversely, a limit below which 
prevalence is tolerated may be more appropriate. Taking into account other contextual factors, 
such as sex differences in prevalence and target achievement as this study found for China 
and Thailand in Asia, an absolute goal addressing low baseline prevalences among women 
while a relative reduction target addressing higher baseline prevalences among men could be 
adopted. Furthermore, in populous countries like China where prevalence was found to be 
declining in this study but population numbers are growing, framing targets in terms of 
numbers of smokers could be more suitable. Thus, while global frameworks may provide a 
starting point, national goals and strategies should ideally be tailored in consultation with 
international organizations such as the WHO, with the involvement of both local and 
international experts and in consideration of the local tobacco context to ensure adoption of 
the most appropriate policies.  
4.7. Limitations 
This study had several limitations. First, the study relied on self-reported data with the 
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potential for reporting bias that could vary across settings and over time. However, validation 
exercises involving biomarkers in high-income settings have found self-reported smoking 
behavior to have high sensitivities (>90%) [147, 148], and cross-country surveys used in 
developing settings employ scientific and evidence-based protocols to ensure comparability 
across settings and over time [149]. Despite quality control efforts, residual variability due to 
systematic differences in survey design may persist, which could influence the magnitude of, 
and/or overstate uncertainty around the estimates. During model development however, 
external validation against IHME estimates, which involved adjustment between different 
survey definitions and questions, demonstrated robustness of the model estimates to such 
systematic variability. Second, the need to conduct projections necessarily places restrictions 
on the model choices. While use of a functional form in the model enabled projection beyond 
the timeframe of the data, all projection estimates are subject to the standard limitations of 
projections based on a functional assumption regardless of the sophistication of the Bayesian 
hierarchical approach. Third, the study does not include estimates for smokeless tobacco, 
which is an important form of tobacco use in some countries and time periods. Unfortunately 
more severe limitations in availability and quality of data on smokeless relative to smoked 
forms [55] and the analytic complications of incorporating and ensuring consistency in a 
larger number of tobacco use indicators in the model precluded the inclusion of smokeless 
tobacco in this study. However, smokeless tobacco may have very different risk factors and 
use profiles than smoked tobacco [142], and may be better modeled in a separate study 
focusing on countries known to have appreciable prevalence of this form, rather than as a 
single indicator in a global study. Fourth, there may also be misclassification bias among 
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users of electronic cigarettes which were excluded, but given the very recent and still limited 
uptake of these devices in most countries and that use is predominantly among current 
smokers [74], any potential impact on the estimates is likely to be negligible. Lastly, while a 
formal impact evaluation of the FCTC has not been conducted, there is some evidence that it 
accelerated adoption of certain tobacco control measures [150] and it is possible for a future 
shift to occur after country ratification which may not be fully captured in our basis period for 
projection. However, varying lags in actual tobacco control implementation after and existing 
tobacco control policies in place before FCTC ratification also preclude using year of FCTC 
country ratification as the base point for projections. Instead, a common starting point was 
used that allows for a more straightforward comparison of projections and provides a 
common reference point from which to examine country differences in actual implementation 
of tobacco control measures. 
  
  93 
5. CONCLUSIONS AND RECOMMENDATIONS 
Global progress in tobacco control has been achieved but remaining challenges require 
effective policy and action.  
5.1. Conclusions 
Globally, smoking prevalence trends are decreasing but tobacco use reduction targets remain 
out of reach for many countries, especially in the developing world. Global tobacco control 
efforts over the past decades have been successful, and the majority of countries have 
experienced declines in smoking prevalence for both men and women. Despite global 
progress, there currently remains wide variation in national smoking prevalence reflective of 
differences in tobacco epidemic stages and in control efforts between countries. Even if 
global declines continue, many countries will not achieve the 30% reduction target for either 
men or women, and because of population growth, there will be more than one billion 
smokers by 2025. Striking country disparities in smoking prevalence will also persist, with 
several low-income and middle-income nations in Africa and in the Eastern Mediterranean at 
risk of worsening smoking epidemics. Such cross-national differences in tobacco control 
scenarios at times also render the WHO global monitoring framework inadequate or 
inappropriate as national goals. 
5.2. Recommendations 
Tobacco control challenges can be addressed by effective policy and action. While the WHO 
global monitoring framework is valuable for political attention and commitment and for civil 
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society involvement, targets set globally should be reviewed for country implementation and 
national tobacco control strategies should be tailored in consultation with international 
organizations such as the WHO, with the involvement of both local and international experts 
and in consideration of the local tobacco context to ensure adoption of the most appropriate 
policies. Whether targets are locally tailored or designed to align with global goals, certain 
general courses of action can be taken to achieve tobacco control goals at the national level. 
Countries in the initial stages of the smoking epidemic should take pre-emptive action and 
invest in tobacco control strategies. Those with smoking prevalence trends on the rise or not 
declining fast enough to meet reduction targets must intensify efforts to curb the smoking 
epidemic. Even countries with desirable trajectories are required to maintain the effectiveness 
of their tobacco control measures. Given evidence for the effectiveness of FCTC-based 
policies in smoking prevalence reduction [133, 150], immediate and comprehensive 
implementation of MPOWER measures to the highest WHO-endorsed levels [13, 48] and 
their strong and sustained enforcement is recommended. These demand reduction strategies 
include: 
• Comprehensive smoking bans in public places. The WHO endorses enactment of 
complete smoke-free legislation in all public places inclusive of healthcare, 
educational and government facilities, indoor workplaces, restaurants, pubs and bars 
and public transport. Completeness entails no allowances for exemptions such as 
designated smoking areas [48] since evidence shows that more comprehensive 
legislation is associated with larger positive health impacts [151]. Lebanon’s 
comprehensive national 100% smoke-free legislation of 2012 [48] could serve as a 
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template. 
• Tobacco dependence treatment reimbursable from the government. The WHO 
recommends smoking cessation programs integrated in the health-care system and in 
coordinated national tobacco control programs. Nicotine replacement therapy should 
also be included in the national Essential Medicines list and free national cessation 
hotlines be made available. Thailand’s effective approach to cost-covered cessation 
services including its nationwide toll-free quit line 1600 set-up in 2009—which 
increased smoking cessation rates [48]—could serve as an example. 
• Health warnings on tobacco product packaging covering at least 30% of the principal 
display areas [48]. Large picture-based designs are evidenced to be significantly more 
effective than smaller text-based warnings [152]. 
• Marketing restrictions involving bans on both direct advertising on national media 
and on indirect advertising such as promotion and sponsorships. Bans on indirect 
advertising are recommended to cover point-of-sale, free product distribution, 
discounts, tobacco branding on non-tobacco products and events including corporate 
social responsibility initiatives. Iran’s enactment of a complete tobacco advertising 
ban entailing financial sanctions within its Comprehensive National Tobacco Control 
Act 2006 [48] is a good illustration. 
• Taxation. The WHO currently endorses >75% of the retail price as tax as the highest 
level of achievement. Excise taxes applied exclusively to tobacco have the strongest 
influence on substantially increasing tobacco product prices and thereby reducing 
consumption. Levying other indirect taxes—import duties and value added taxes—is 
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also preferred over direct taxation such as corporate tax [48]. Evidence also suggests 
that a uniform and specific taxation structure is most effective for consumption and 
prevalence reduction [153]. The Philippine sin tax bill of 2012 enacting a 
restructuring of the local tobacco taxation system demonstrates a step in the right 
direction [154]. 
 
To further accelerate declines and to avoid potentially stagnating trends, development of and 
prudent implementation of innovative demand-side and supply-side tobacco control measures 
would be helpful. Recently-developed demand reduction measures with initial evidence of 
effectiveness such as plain cigarette packaging [155] should be scaled-up at a global level. 
Implementation of supply-side innovations such as restructuring the tobacco market, 
production price controls, phasing-out of commercial tobacco sales or legislated industry 
public health targets should be initiated. The “Help End Addiction to Lethal Tobacco Habits 
(HEALTH) Act” proposed in the United States senate [40] could serve as a starting point for 
implementing performance-based regulations. 
 
Finally, international cooperation and multisectoral approaches should be fostered in order to 
overcome tobacco industry interference [49, 50] and enhance country capacity, which is a 
factor in tobacco control implementation [143]. Rallying civil society support [130] and 
creating initiatives to aid countries, especially those most vulnerable to tobacco company 
pressure, in overcoming tobacco industry tactics are strongly encouraged. Civil society 
engagement was instrumental in the progress of tobacco control among developing settings in 
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Latin America [131, 156]. In the aftermath of international media attention on tobacco 
industry threats against severely resource-limited African governments, the global fund to 
help countries defend tobacco control unveiled by Bloomberg Philanthropies and the Bill and 
Melinda Gates Foundation at the 2015 World Conference on Tobacco or Health [51] is one 
potential milestone in international and mutltisectoral collaboration in tobacco control. 
Finally, public-private partnerships aimed at enhancing country capacity, such as the African 
Capacity Building Foundation, are one pathway that should be well-utilized by governments 
especially in vulnerable regions [157]. 
5.3. Future research directions 
Effecting policy and action entails awareness, advocacy and reinvigoration of political 
commitment. For such purposes, research is important to further characterize the tobacco 
epidemic, to assess its impact and to identify the most efficient pathways for curbing it. 
Future research directions include: 
• Smokeless tobacco use trends estimation and projection. The health effects of 
smokeless tobacco use cannot be discounted and their impact on countries where 
smokeless forms are common should be assessed while ensuring consistency with 
smoking prevalence estimates. 
• Country-specific assessment of major tobacco use determinants via modeling 
approaches to identify and/or quantify the influence of drivers such as income, 
sociocultural aspects of tobacco use initiation and cessation, and the effect of specific 
tobacco control measures on tobacco use prevalence. 
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• Tobacco-attributable mortality estimation and projection under a comparative risk 
assessment framework.  
• Tobacco use projections under different intervention scenarios. Dynamic 
mathematical models or Bayesian hierarchical models may be developed to assess the 
impact of implementing different combinations of tobacco control policies on tobacco 
use prevalence. 
 
Tobacco control remains a global priority. Remarkable achievements have been made in 
global tobacco control efforts but challenges remain in reaching tobacco use reduction targets 
and resolving striking country disparities in smoking prevalence. If immediate, effective and 
sustained action is undertaken, desirable trajectories may be attained and maintained towards 
global convergence in tobacco use elimination.
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Appendix A: Regional priors for men 
Region Mean 
βtime βperiod βtimexperiod βsmkd βcigc βcigd 
Africa, Central 0.95 -0.30 0.95 -0.30 -0.40 -0.45 
Africa, East -0.17 -0.30 -0.22 -0.31 -0.10 -0.30 
Africa, East Islands 0.03 -0.23 -0.28 -0.21 -0.08 -0.30 
Africa, North -0.02 0.01 0.19 -0.09 -0.16 -0.29 
Africa, South 0.00 -0.39 0.29 -0.16 -0.20 -0.41 
Africa, West 0.15 -0.59 0.48 -0.11 -0.30 -0.37 
America, Central -0.19 -0.55 -0.41 -0.53 -0.05 -0.46 
America, North -0.06 -0.15 -0.66 -0.29 -0.03 -0.27 
America, South -0.41 -0.03 -0.22 -0.31 -0.07 -0.34 
Asia, East 0.04 -0.27 -0.42 -0.09 -0.05 -0.10 
Asia, South 0.65 -0.60 -0.92 -0.15 -0.37 -0.53 
Asia, Southeast -0.13 0.04 0.05 -0.13 -0.06 -0.18 
Asia, West 0.57 -0.41 0.06 -0.06 -0.13 -0.25 
Australasia -0.08 -0.24 -0.52 -0.13 -0.04 -0.10 
Caribbean 0.08 -0.54 -0.15 -0.25 -0.12 -0.45 
Europe, East -0.88 0.24 0.56 -0.14 -0.02 -0.14 
Europe, North -0.41 -0.17 -0.38 -0.34 -0.20 -0.31 
Europe, South -0.43 0.10 0.16 -0.07 -0.03 -0.10 
Europe, West 0.24 -0.02 -0.74 -0.18 -0.03 -0.20 
Polynesia -0.18 0.04 -0.21 -0.17 -0.10 -0.32 
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Appendix B: Regional priors for women 
Region Mean 
βtime βperiod βtimexperiod βsmkd βcigc βcigd 
Africa, Central 0.09 -0.14 0.09 -0.40 -0.66 -1.15 
Africa, East -0.13 0.02 -0.32 -0.50 -1.22 -1.22 
Africa, East Islands -0.34 0.00 -0.55 -0.33 -0.37 -1.01 
Africa, North -0.71 -0.16 -0.83 -0.42 -0.61 -1.08 
Africa, South -0.23 -0.01 -0.24 -0.23 -0.48 -0.68 
Africa, West -0.67 -1.37 -0.10 -0.19 -1.34 -1.35 
America, Central -0.48 -0.43 -0.25 -0.57 -0.09 -0.56 
America, North 0.00 -0.12 -1.07 -0.30 -0.03 -0.28 
America, South 0.15 0.08 -0.92 -0.36 -0.06 -0.54 
Asia, East 0.67 -0.67 -1.31 -0.21 -0.06 -0.23 
Asia, South -0.61 0.28 -0.95 -0.18 -0.57 -0.79 
Asia, Southeast 0.15 -0.08 -0.78 -0.25 -0.08 -0.33 
Asia, West 1.73 -1.05 -1.46 -0.32 -0.31 -1.39 
Australasia -0.24 -0.17 -0.45 -0.12 -0.04 -0.10 
Caribbean 0.15 -0.58 -0.88 -0.18 -0.17 -0.38 
Europe, East -0.04 0.10 -0.30 -0.27 -0.06 -0.22 
Europe, North -0.28 -0.20 -0.42 -0.33 -0.14 -0.21 
Europe, South -0.02 0.03 -0.30 -0.15 -0.08 -0.17 
Europe, West 0.62 0.00 -0.98 -0.14 -0.03 -0.11 
Polynesia -0.05 -0.04 -0.25 -0.25 -0.19 -0.37 
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Appendix C: Current tobacco smoking prevalence estimates (15+ age-standardized) 
Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Albania Men 57.5 44.7 68.6 53.6 42.5 66.6 48.9 29.0 73.8 
Albania Women 11.6 8.6 15.0 8.6 6.1 11.5 5.6 2.6 9.2 
Algeria Men 24.7 12.5 38.3 27.2 18.2 37.2 34.4 12.5 60.0 
Algeria Women 4.6 1.9 7.6 1.7 1.0 2.5 0.4 0.1 0.7 
Andorra Men 42.9 31.4 56.0 39.0 30.3 51.3 35.3 17.9 56.0 
Andorra Women 31.1 21.2 41.5 28.6 19.9 38.2 25.9 12.5 43.0 
Argentina Men 43.3 32.5 54.6 33.6 27.8 39.5 23.5 14.5 33.1 
Argentina Women 34.3 26.4 44.0 22.5 18.3 27.1 12.2 7.6 16.9 
Armenia Men 67.1 54.3 79.3 56.8 46.7 66.3 44.9 30.9 59.4 
Armenia Women 2.6 2.1 3.3 1.8 1.5 2.2 1.1 0.7 1.6 
Australia Men 26.9 21.6 31.9 19.4 16.2 22.8 12.1 8.5 15.9 
Australia Women 23.2 18.8 27.9 15.8 12.9 18.5 9.0 6.2 11.7 
Austria Men 47.5 34.3 61.9 39.7 28.8 53.8 31.3 16.2 47.2 
Austria Women 40.3 28.4 51.5 35.7 25.2 46.3 30.3 15.4 45.1 
Azerbaijan Men 56.2 28.2 90.0 48.0 24.6 75.6 38.9 14.1 69.9 
Azerbaijan Women 0.6 0.3 1.1 0.5 0.2 0.8 0.3 0.1 0.6 
Bahamas Men 13.1 7.1 22.0 12.6 6.3 20.1 13.0 3.7 27.8 
Bahamas Women 3.9 1.6 6.9 2.6 1.0 4.4 1.5 0.2 3.2 
Bahrain Men 17.9 13.3 22.2 34.7 25.7 43.3 85.3 53.5 100.0 
Bahrain Women 4.8 3.3 6.1 6.7 4.5 9.4 11.7 3.7 20.9 
Bangladesh Men 63.5 49.6 78.8 46.2 38.5 55.1 29.3 17.6 40.2 
Bangladesh Women 6.2 4.0 8.4 1.5 1.0 1.9 0.2 0.0 0.3 
  120 
Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Belgium Men 35.6 25.1 47.9 29.0 19.1 37.8 21.6 12.3 34.1 
Belgium Women 24.9 15.9 34.8 21.9 13.4 31.2 18.4 9.5 30.5 
Belize Men 33.6 10.9 67.5 23.0 8.0 46.4 14.0 2.5 32.9 
Belize Women 3.4 0.7 7.4 2.2 0.5 4.6 1.2 0.2 2.9 
Benin Men 12.3 7.7 17.3 15.6 11.7 19.5 23.3 13.2 36.7 
Benin Women 1.6 0.8 2.4 1.1 0.7 1.6 0.7 0.3 1.2 
Bolivia Men 50.7 32.1 70.4 35.5 19.9 53.4 21.9 7.4 42.3 
Bolivia Women 26.4 17.4 38.2 19.3 11.7 28.8 12.7 4.6 23.7 
Bosnia Herzegovina Men 57.8 43.4 73.3 49.9 36.7 63.7 41.2 21.9 66.6 
Bosnia Herzegovina Women 36.4 28.7 46.9 31.6 23.7 40.6 26.5 13.4 42.7 
Botswana Men 30.8 20.1 43.8 34.8 24.3 46.0 43.7 19.4 71.3 
Botswana Women 8.5 4.9 13.2 6.8 4.2 10.2 5.0 1.9 8.5 
Brazil Men 29.8 22.3 37.6 22.1 17.7 26.3 14.4 8.4 21.3 
Brazil Women 18.4 14.1 23.1 13.2 10.7 16.4 8.3 4.8 12.4 
Brunei Darussalam Men 28.6 14.4 45.2 27.9 12.8 45.9 29.1 6.6 67.4 
Brunei Darussalam Women 4.9 2.6 8.0 3.4 1.5 6.0 2.2 0.4 5.1 
Bulgaria Men 59.7 42.2 78.3 47.5 38.7 58.7 34.7 20.4 52.6 
Bulgaria Women 42.6 29.0 56.7 32.1 25.2 40.5 21.7 11.3 33.0 
Burkina Faso Men 24.0 16.9 31.8 31.5 22.1 41.6 50.0 21.7 85.3 
Burkina Faso Women 8.5 5.1 12.5 5.5 3.0 8.3 3.0 0.9 5.8 
Burundi Men 22.6 9.0 38.5 18.5 8.7 30.6 14.3 4.9 26.3 
Burundi Women 4.5 1.4 8.8 3.6 1.3 6.8 2.7 0.9 5.6 
Cambodia Men 51.5 35.2 68.3 45.8 35.0 57.0 40.4 20.3 68.7 
Cambodia Women 8.0 6.1 10.0 4.0 3.2 4.9 1.4 0.8 2.1 
Cameroon Men 12.2 6.0 19.5 27.9 17.4 40.1 85.4 57.2 100.0 
Cameroon Women 0.9 0.3 1.6 0.9 0.3 1.6 1.0 0.2 1.8 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Canada Men 29.4 25.1 34.2 20.9 17.5 24.3 12.6 9.8 15.4 
Canada Women 26.5 22.5 30.6 15.8 13.3 18.3 7.3 5.7 8.8 
Cape Verde Men 14.6 7.9 21.7 19.5 11.7 28.5 31.7 11.0 54.9 
Cape Verde Women 5.9 3.3 8.6 4.1 2.5 5.9 2.6 1.1 4.7 
Chad Men 15.3 11.2 19.9 36.3 24.0 50.9 93.7 65.6 100.0 
Chad Women 3.1 2.0 4.3 3.4 2.0 4.8 4.0 1.5 7.7 
Chile Men 50.0 36.9 63.8 43.2 33.0 55.3 35.5 19.0 54.9 
Chile Women 43.7 31.9 55.8 37.4 27.2 47.0 30.4 16.3 46.4 
China Men 56.5 43.4 72.3 49.7 40.9 58.4 41.9 25.8 56.6 
China Women 3.5 2.6 4.6 2.2 1.8 2.7 1.1 0.7 1.7 
Colombia Men 24.8 10.0 43.5 18.5 8.5 30.4 12.5 3.5 22.6 
Colombia Women 10.2 4.3 16.7 7.3 3.4 11.9 4.6 1.5 8.8 
Comoros Men 30.3 22.0 40.3 25.5 19.6 33.9 20.5 9.9 32.0 
Comoros Women 14.4 8.6 21.4 8.1 4.7 12.1 3.6 1.0 6.8 
Congo Men 10.1 6.9 13.9 26.7 19.1 35.1 93.8 73.1 100.0 
Congo Women 1.6 0.7 2.4 1.6 0.8 2.5 1.9 0.6 3.4 
Cook Islands Men 50.7 31.7 69.7 41.5 24.1 58.0 32.4 10.5 61.4 
Cook Islands Women 40.1 26.3 58.6 34.6 22.0 51.0 29.7 11.4 57.6 
Costa Rica Men 28.0 17.0 41.0 20.7 12.7 30.6 14.2 4.4 27.5 
Costa Rica Women 14.1 7.1 22.6 10.0 5.5 15.7 6.4 1.8 12.9 
Cote d'Ivoire Men 25.7 11.7 44.2 33.3 18.1 52.4 51.5 22.6 84.4 
Cote d'Ivoire Women 2.7 1.1 4.7 1.9 0.9 3.0 1.1 0.3 1.9 
Croatia Men 40.5 30.8 50.9 39.6 30.7 47.8 39.2 24.8 58.7 
Croatia Women 28.1 21.1 35.3 31.4 24.1 37.8 38.4 23.1 55.0 
Cuba Men 54.1 34.4 76.1 51.8 31.0 81.4 50.1 20.6 100.0 
Cuba Women 31.7 18.2 47.7 22.1 11.0 34.0 13.9 3.3 28.4 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Cyprus Men 60.6 40.7 87.1 53.8 36.4 73.9 46.0 21.3 75.8 
Cyprus Women 22.3 12.1 34.3 19.4 11.9 28.3 16.3 7.7 27.8 
Czech Republic Men 40.9 32.8 49.6 38.2 31.1 45.1 35.2 22.7 49.3 
Czech Republic Women 29.3 23.4 35.5 29.1 23.7 34.2 28.8 19.5 40.0 
Democratic Republic of the Congo Women 2.3 0.3 5.7 2.5 0.4 6.0 3.0 0.3 7.3 
Denmark Men 41.0 31.6 50.4 23.6 19.1 28.8 10.6 6.8 15.0 
Denmark Women 34.7 27.2 42.4 21.1 17.0 25.7 10.0 6.3 13.8 
Djibouti Men 31.7 16.3 52.0 26.6 12.7 45.9 21.6 5.4 42.1 
Djibouti Women 2.9 1.6 4.7 2.4 1.1 3.8 1.9 0.5 3.6 
Dominica Men 15.7 8.4 26.0 14.9 8.7 22.0 14.6 5.4 27.1 
Dominica Women 2.6 1.1 4.2 1.7 0.9 2.6 1.0 0.2 1.9 
Dominican Republic Men 21.4 15.8 26.8 20.0 13.4 25.6 18.8 8.3 33.3 
Dominican Republic Women 15.3 11.3 19.5 11.0 7.4 14.1 7.0 2.4 11.9 
Ecuador Men 21.4 15.5 28.9 16.3 10.8 22.1 11.3 4.1 19.7 
Ecuador Women 5.3 3.1 7.5 3.7 2.3 5.8 2.3 0.8 4.4 
Egypt Men 34.8 23.4 46.4 43.8 35.0 52.3 63.8 36.8 97.7 
Egypt Women 1.2 0.7 1.8 0.5 0.3 0.7 0.1 0.1 0.3 
El Salvador Men 38.1 17.0 65.9 26.4 10.8 45.0 16.7 3.1 35.2 
El Salvador Women 5.7 2.5 9.3 3.7 1.5 6.2 2.2 0.5 4.8 
Eritrea Men 23.8 8.3 39.6 20.1 8.2 34.7 16.5 3.6 31.7 
Eritrea Women 1.0 0.1 2.2 0.8 0.2 1.8 0.7 0.1 1.6 
Estonia Men 54.8 44.8 66.6 45.8 37.5 55.4 34.7 23.5 49.4 
Estonia Women 27.3 22.2 33.0 25.6 21.1 30.9 24.0 15.8 32.4 
Ethiopia Men 9.3 6.1 12.6 8.9 6.6 11.2 8.8 4.4 13.9 
Ethiopia Women 0.6 0.3 0.9 0.5 0.3 0.8 0.4 0.2 0.8 
  123 
 
Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Fiji Men 52.1 30.0 78.6 42.5 18.6 66.9 33.1 7.1 68.1 
Fiji Women 15.4 8.4 24.0 13.2 6.7 22.1 11.3 2.9 24.1 
Finland Men 33.7 26.7 39.8 26.3 22.1 31.1 18.3 12.8 24.2 
Finland Women 25.2 20.5 30.0 20.6 17.1 24.2 15.1 11.0 19.4 
France Men 38.1 29.0 50.2 32.4 23.6 41.0 25.9 15.3 38.9 
France Women 27.8 20.6 35.9 25.8 19.7 32.6 23.8 13.3 34.9 
Gabon Men 14.7 7.9 22.0 33.6 23.1 45.3 95.1 75.6 100.0 
Gabon Women 5.7 2.4 10.2 6.1 2.6 10.2 7.2 2.8 12.8 
Gambia Men 29.0 16.6 42.3 37.8 27.3 50.0 58.4 32.5 93.1 
Gambia Women 1.7 0.8 2.8 1.2 0.6 1.8 0.7 0.3 1.3 
Georgia Men 63.6 50.3 80.0 58.7 45.7 72.6 53.6 31.9 81.3 
Georgia Women 6.5 4.8 8.1 6.0 4.6 7.5 5.5 3.0 8.3 
Germany Men 38.4 31.2 45.1 33.9 28.6 40.9 28.6 19.1 36.2 
Germany Women 30.2 24.8 35.7 29.3 23.6 34.9 28.0 19.7 36.5 
Ghana Men 9.2 6.5 12.5 11.5 7.9 16.0 16.7 6.2 28.7 
Ghana Women 0.8 0.5 1.1 0.5 0.3 0.8 0.3 0.1 0.6 
Greece Men 62.4 37.7 87.9 55.3 38.8 71.3 47.8 28.0 73.4 
Greece Women 42.1 23.5 62.7 35.7 24.3 50.1 29.2 14.0 48.1 
Grenada Men 34.8 12.6 67.4 32.8 13.2 55.9 32.0 11.3 60.8 
Grenada Women 8.5 2.3 16.4 5.7 1.8 9.8 3.3 0.8 6.7 
Guatemala Men 24.3 8.6 43.7 16.6 5.3 29.8 10.3 1.8 22.7 
Guatemala Women 4.5 1.1 9.0 3.0 0.5 5.6 1.7 0.1 3.7 
Guinea Women 4.9 1.3 9.8 3.6 0.9 7.0 2.3 0.5 5.1 
Guyana Men 60.1 36.4 90.6 44.9 30.3 64.5 30.5 13.8 51.0 
Guyana Women 6.3 2.7 10.4 4.4 2.3 7.3 2.6 1.0 4.8 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Haiti Men 18.6 11.5 25.8 21.1 13.5 29.4 26.3 11.6 47.5 
Haiti Women 3.9 2.5 5.6 2.9 1.7 4.1 1.9 0.6 3.6 
Honduras Men 60.1 35.3 100.0 40.1 28.8 55.0 23.3 10.2 37.9 
Honduras Women 4.1 1.6 6.5 2.5 1.5 3.9 1.4 0.5 2.5 
Hungary Men 46.5 34.7 58.8 36.1 28.4 44.2 25.1 15.0 37.2 
Hungary Women 34.9 26.5 43.1 27.7 21.9 34.1 20.0 12.7 29.7 
Iceland Men 32.7 19.5 47.1 20.8 14.2 27.8 11.1 5.2 18.5 
Iceland Women 26.7 17.1 36.5 18.2 13.5 23.3 10.7 5.7 17.2 
India Men 36.3 24.7 50.1 24.4 19.6 29.9 14.4 6.9 23.3 
India Women 7.1 4.6 10.0 3.0 2.4 3.6 0.8 0.3 1.5 
Indonesia Men 56.4 43.1 73.6 68.5 55.5 82.7 87.0 64.5 100.0 
Indonesia Women 6.0 4.5 7.8 4.2 3.3 5.1 2.5 1.5 3.6 
Iran Men 29.9 20.9 40.4 24.4 19.7 29.5 18.9 8.8 30.9 
Iran Women 5.6 3.4 7.7 1.5 1.1 2.0 0.2 0.1 0.4 
Iraq Men 31.3 20.0 42.6 43.0 30.0 55.7 69.7 34.4 100.0 
Iraq Women 5.4 3.2 8.6 6.3 3.6 9.3 8.4 2.9 16.9 
Ireland Men 47.0 24.4 69.7 35.7 22.2 54.2 24.2 10.4 42.8 
Ireland Women 40.7 24.7 58.7 31.9 21.4 47.3 22.9 9.8 41.2 
Israel Men 43.4 32.9 56.1 42.3 30.4 55.3 42.2 21.9 70.3 
Israel Women 22.6 17.1 29.5 20.3 14.5 27.1 18.2 8.8 31.2 
Italy Men 32.6 27.6 39.2 29.5 24.8 34.7 25.8 19.6 33.0 
Italy Women 20.3 16.5 24.0 19.9 16.8 23.6 19.6 14.3 25.0 
Jamaica Men 28.7 19.5 40.7 28.3 17.6 42.6 29.1 9.4 54.3 
Jamaica Women 9.2 5.6 13.5 6.8 3.9 10.6 4.6 1.4 9.0 
Japan Men 56.3 44.0 67.6 43.1 35.0 53.0 29.0 19.4 40.1 
Japan Women 16.6 13.3 21.4 13.2 10.9 16.4 9.6 6.3 13.4 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Jordan Men 42.4 25.5 59.2 59.1 41.2 78.0 85.7 52.0 100.0 
Jordan Women 7.7 4.9 11.2 9.4 6.2 12.8 13.2 5.5 22.5 
Kazakhstan Men 58.0 47.7 71.1 47.2 38.2 57.2 35.5 21.8 52.2 
Kazakhstan Women 11.4 8.7 14.5 10.1 7.5 12.7 8.7 4.7 14.6 
Kenya Men 31.2 23.7 41.4 26.3 19.7 34.0 20.7 10.0 32.8 
Kenya Women 3.1 2.1 4.2 2.4 1.6 3.4 1.7 0.6 2.9 
Kiribati Men 82.6 64.3 100.0 68.6 47.7 89.9 52.5 20.7 90.7 
Kiribati Women 50.0 34.6 66.2 43.8 31.0 57.5 38.2 16.5 70.9 
Kuwait Men 32.9 20.8 44.8 45.8 32.8 63.0 72.3 38.7 100.0 
Kuwait Women 5.1 3.0 7.1 5.9 3.6 8.2 8.0 2.6 15.8 
Kyrgyzstan Men 51.3 39.4 64.0 50.0 40.3 60.0 49.0 33.0 67.4 
Kyrgyzstan Women 4.9 3.3 6.7 3.9 2.7 5.2 2.9 1.5 4.6 
Lao People's Dem. Rep. Men 74.1 55.1 93.3 61.9 48.1 76.7 47.8 27.2 69.1 
Lao People's Dem. Rep. Women 20.6 15.2 26.6 11.8 8.7 14.7 5.3 2.8 8.0 
Latvia Men 57.3 45.8 69.2 51.8 41.6 62.4 45.1 31.2 63.6 
Latvia Women 25.1 20.0 30.3 24.5 19.8 30.1 24.0 15.4 33.1 
Lebanon Men 35.4 24.0 48.3 41.6 31.8 52.0 55.5 30.9 87.3 
Lebanon Women 24.4 16.1 34.9 28.5 20.8 35.7 37.7 17.2 58.2 
Lesotho Men 35.4 21.6 50.0 47.9 35.7 62.2 74.3 46.7 100.0 
Lesotho Women 0.6 0.2 1.0 0.5 0.2 0.8 0.4 0.1 0.7 
Liberia Men 19.4 8.8 32.6 24.3 12.9 39.5 35.8 14.1 65.5 
Liberia Women 4.1 1.9 7.2 2.9 1.4 4.7 1.8 0.6 3.2 
Libya Men 53.2 28.6 82.3 58.2 41.5 76.9 67.8 34.8 100.0 
Libya Women 1.0 0.3 1.9 0.4 0.1 0.7 0.1 0.0 0.2 
Lithuania Men 53.1 42.3 65.0 42.4 33.1 52.2 30.6 17.4 46.4 
Lithuania Women 21.3 16.8 26.2 21.5 16.9 26.7 22.4 12.8 32.6 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Luxembourg Men 34.0 26.1 42.8 28.4 21.5 34.8 22.3 11.7 32.9 
Luxembourg Women 25.7 19.9 32.8 22.7 17.8 27.7 19.3 11.2 28.7 
Madagascar Men 47.5 28.3 69.1 41.5 29.1 54.9 36.2 18.3 58.5 
Madagascar Women 4.1 2.0 7.1 2.7 1.2 4.5 1.5 0.5 2.8 
Malawi Men 33.0 25.0 40.4 27.6 21.0 34.0 21.7 12.2 31.1 
Malawi Women 9.5 6.0 13.3 6.8 4.1 9.5 4.3 1.7 7.6 
Malaysia Men 54.8 39.7 70.7 46.3 33.9 58.7 38.0 17.2 68.7 
Malaysia Women 3.2 2.2 4.2 1.8 1.2 2.4 0.9 0.3 1.7 
Maldives Men 49.1 28.3 77.1 40.4 28.8 51.7 32.8 12.7 55.1 
Maldives Women 12.6 7.0 19.9 5.0 3.5 6.9 1.3 0.6 2.3 
Mali Men 20.6 15.7 26.9 29.7 22.6 39.6 52.6 24.7 84.8 
Mali Women 4.1 2.0 6.4 3.5 1.9 5.4 3.0 1.2 5.5 
Malta Men 39.0 29.2 48.6 32.6 24.8 40.5 25.4 12.8 39.6 
Malta Women 26.4 19.6 34.6 22.4 16.9 27.8 18.2 9.0 28.1 
Marshall Islands Men 40.0 28.8 56.4 33.6 20.5 49.2 27.3 8.3 51.9 
Marshall Islands Women 6.4 3.9 9.2 5.6 3.1 8.3 5.0 1.3 10.0 
Mauritania Men 24.0 18.3 31.1 35.3 25.6 45.6 62.9 31.8 96.1 
Mauritania Women 5.7 3.8 8.1 4.2 2.8 5.8 2.9 1.3 5.0 
Mauritius Men 46.4 35.9 56.6 42.4 32.5 52.4 37.9 18.5 57.6 
Mauritius Women 4.8 3.5 6.2 3.7 2.7 4.6 2.6 1.4 4.2 
Mexico Men 37.2 30.3 44.4 24.8 20.7 29.3 13.8 9.2 18.2 
Mexico Women 13.1 10.4 16.1 8.4 6.8 9.9 4.3 2.9 5.9 
Mongolia Men 56.9 40.3 73.6 50.3 41.2 60.3 43.4 27.2 61.3 
Mongolia Women 9.3 6.5 12.6 6.3 5.0 7.8 3.7 2.1 5.5 
Morocco Men 33.6 25.0 42.2 40.1 29.8 50.9 53.9 25.0 91.3 
Morocco Women 4.0 2.4 5.9 1.9 1.1 2.7 0.7 0.2 1.4 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Luxembourg Men 34.0 26.1 42.8 28.4 21.5 34.8 22.3 11.7 32.9 
Luxembourg Women 25.7 19.9 32.8 22.7 17.8 27.7 19.3 11.2 28.7 
Madagascar Men 47.5 28.3 69.1 41.5 29.1 54.9 36.2 18.3 58.5 
Madagascar Women 4.1 2.0 7.1 2.7 1.2 4.5 1.5 0.5 2.8 
Malawi Men 33.0 25.0 40.4 27.6 21.0 34.0 21.7 12.2 31.1 
Malawi Women 9.5 6.0 13.3 6.8 4.1 9.5 4.3 1.7 7.6 
Malaysia Men 54.8 39.7 70.7 46.3 33.9 58.7 38.0 17.2 68.7 
Malaysia Women 3.2 2.2 4.2 1.8 1.2 2.4 0.9 0.3 1.7 
Maldives Men 49.1 28.3 77.1 40.4 28.8 51.7 32.8 12.7 55.1 
Maldives Women 12.6 7.0 19.9 5.0 3.5 6.9 1.3 0.6 2.3 
Mali Men 20.6 15.7 26.9 29.7 22.6 39.6 52.6 24.7 84.8 
Mali Women 4.1 2.0 6.4 3.5 1.9 5.4 3.0 1.2 5.5 
Malta Men 39.0 29.2 48.6 32.6 24.8 40.5 25.4 12.8 39.6 
Malta Women 26.4 19.6 34.6 22.4 16.9 27.8 18.2 9.0 28.1 
Marshall Islands Men 40.0 28.8 56.4 33.6 20.5 49.2 27.3 8.3 51.9 
Marshall Islands Women 6.4 3.9 9.2 5.6 3.1 8.3 5.0 1.3 10.0 
Mauritania Men 24.0 18.3 31.1 35.3 25.6 45.6 62.9 31.8 96.1 
Mauritania Women 5.7 3.8 8.1 4.2 2.8 5.8 2.9 1.3 5.0 
Mauritius Men 46.4 35.9 56.6 42.4 32.5 52.4 37.9 18.5 57.6 
Mauritius Women 4.8 3.5 6.2 3.7 2.7 4.6 2.6 1.4 4.2 
Mexico Men 37.2 30.3 44.4 24.8 20.7 29.3 13.8 9.2 18.2 
Mexico Women 13.1 10.4 16.1 8.4 6.8 9.9 4.3 2.9 5.9 
Mongolia Men 56.9 40.3 73.6 50.3 41.2 60.3 43.4 27.2 61.3 
Mongolia Women 9.3 6.5 12.6 6.3 5.0 7.8 3.7 2.1 5.5 
Morocco Men 33.6 25.0 42.2 40.1 29.8 50.9 53.9 25.0 91.3 
Morocco Women 4.0 2.4 5.9 1.9 1.1 2.7 0.7 0.2 1.4 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Mozambique Men 41.7 22.4 61.3 34.2 23.4 47.7 26.7 12.5 41.5 
Mozambique Women 7.5 4.1 12.4 6.2 3.1 9.9 4.9 1.7 9.0 
Myanmar Men 56.1 41.7 74.3 38.4 28.7 49.5 23.0 10.0 39.8 
Myanmar Women 16.0 9.6 23.8 8.7 5.0 12.7 3.8 1.1 7.1 
Namibia Men 29.6 22.4 37.7 35.2 24.7 47.1 47.3 22.2 80.3 
Namibia Women 14.6 10.9 18.5 12.2 9.0 16.0 9.7 4.9 16.0 
Nauru Men 57.8 39.5 80.9 47.3 27.4 65.9 36.9 11.6 68.0 
Nauru Women 63.5 43.2 86.1 54.3 36.6 79.3 45.3 13.0 85.4 
Nepal Men 45.7 36.1 55.1 39.7 31.5 47.5 32.6 20.3 47.7 
Nepal Women 34.3 27.0 41.0 15.9 12.6 19.7 5.1 3.1 7.6 
Netherlands Men 36.7 30.5 43.5 28.9 23.9 34.5 20.5 14.1 27.7 
Netherlands Women 31.0 25.7 36.7 25.9 21.7 30.8 19.9 13.3 25.9 
New Zealand Men 30.2 24.9 36.4 20.7 17.2 23.9 11.9 8.5 15.2 
New Zealand Women 29.1 23.7 36.2 19.0 15.8 22.6 10.1 7.4 13.0 
Nicaragua Women 8.0 5.0 11.5 5.2 2.8 8.4 3.0 0.6 6.2 
Niger Men 8.8 6.0 12.6 14.7 10.9 18.2 32.1 16.4 48.5 
Niger Women 0.3 0.1 0.6 0.2 0.1 0.4 0.1 0.0 0.3 
Nigeria Men 10.9 6.0 16.9 14.6 8.1 22.7 23.6 9.2 44.7 
Nigeria Women 2.0 0.8 3.2 1.3 0.5 2.0 0.7 0.2 1.3 
Niue Men 30.6 17.5 47.1 23.0 15.5 29.8 16.0 7.2 25.2 
Niue Women 15.9 8.0 24.7 12.6 8.4 18.4 9.8 3.8 16.7 
Norway Men 43.2 35.4 51.1 27.6 23.8 32.6 14.4 10.9 18.3 
Norway Women 41.5 33.2 48.5 27.1 22.6 31.7 14.4 10.7 17.9 
Oman Men 12.6 9.1 16.4 17.9 11.2 25.5 31.9 10.6 61.7 
Oman Women 0.8 0.4 1.3 1.0 0.4 1.6 1.3 0.3 2.5 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Pakistan Men 37.4 26.8 48.2 40.9 32.0 51.9 48.6 23.4 76.1 
Pakistan Women 8.3 5.6 11.5 4.1 2.9 5.5 1.6 0.6 2.7 
Palau Men 54.9 23.0 90.1 46.5 18.8 89.5 38.0 5.6 92.4 
Palau Women 25.2 7.9 50.1 23.1 6.1 49.0 21.5 3.4 55.9 
Palestine Men 29.4 15.9 44.5 41.0 28.4 53.4 70.0 40.5 100.0 
Palestine Women 2.9 1.6 4.6 3.3 2.2 4.7 4.3 1.9 7.1 
Panama Men 25.0 15.3 34.8 14.1 10.8 17.4 6.4 2.9 10.7 
Panama Women 5.2 3.2 7.0 3.2 2.5 4.1 1.7 0.8 2.8 
Papua New Guinea Men 78.1 58.0 100.0 64.1 45.1 81.7 48.8 20.9 82.5 
Papua New Guinea Women 38.1 23.6 51.5 32.4 22.7 41.5 27.0 11.0 45.3 
Paraguay Men 45.2 33.0 57.8 32.2 22.5 41.8 20.0 10.2 32.1 
Paraguay Women 14.7 10.9 18.8 9.9 7.1 13.4 5.7 2.5 9.3 
Peru Women 9.5 6.4 12.9 6.8 5.4 8.5 4.2 2.5 6.1 
Philippines Men 58.9 45.9 73.0 47.9 39.1 55.9 35.5 22.3 51.3 
Philippines Women 12.8 10.0 16.0 9.8 8.1 11.7 6.6 4.3 9.6 
Poland Men 46.1 32.6 58.1 36.3 30.5 43.6 26.3 15.4 36.8 
Poland Women 37.6 28.2 47.7 27.5 22.8 33.1 17.6 10.7 25.6 
Portugal Men 36.6 27.4 45.7 32.5 25.5 40.0 28.1 16.7 41.4 
Portugal Women 15.4 10.8 20.5 14.1 9.9 18.3 12.8 5.9 21.1 
Qatar Men 18.6 10.6 27.2 27.9 18.6 37.6 53.8 27.8 91.1 
Qatar Women 1.6 0.7 2.7 1.8 0.9 2.9 2.1 0.7 4.0 
Republic of Korea Men 76.0 56.4 93.9 66.0 46.3 86.7 54.3 27.2 88.6 
Republic of Korea Women 6.6 4.0 9.6 5.5 3.1 8.3 4.2 1.6 7.9 
Republic of Moldova Men 40.7 32.2 50.9 43.6 35.4 53.3 49.1 31.3 66.3 
Republic of Moldova Women 5.4 4.1 7.0 5.4 4.2 6.5 5.4 3.3 7.7 
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Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Romania Men 53.3 41.2 66.9 41.7 34.4 50.6 29.6 17.2 44.3 
Romania Women 27.5 20.9 34.8 24.1 19.5 28.7 20.3 11.9 30.1 
Russian Federation Men 68.9 54.1 87.8 61.0 50.0 74.2 52.1 33.4 76.2 
Russian Federation Women 21.8 16.4 28.1 22.3 17.8 26.6 23.6 14.2 33.0 
Rwanda Men 28.8 16.6 41.4 23.8 17.5 30.5 18.9 10.3 28.1 
Rwanda Women 6.8 3.7 10.2 5.9 3.6 8.4 5.1 2.1 8.0 
Saint Kitts and Nevis Men 15.6 8.9 22.9 14.8 9.9 21.0 15.0 5.1 27.3 
Saint Kitts and Nevis Women 1.5 0.6 2.5 1.0 0.4 1.6 0.6 0.1 1.2 
Saint Vincent and the Grenadines Men 28.7 5.3 64.4 28.7 5.9 69.7 29.9 2.3 87.0 
Saint Vincent and the Grenadines Women 5.0 0.8 11.2 3.4 0.5 8.0 2.2 0.2 6.0 
Samoa Men 62.1 41.3 86.8 47.7 36.4 60.2 33.5 17.9 54.2 
Samoa Women 26.6 16.8 37.1 21.2 15.4 27.3 15.9 7.0 24.9 
Sao Tome and Principe Men 4.9 2.8 7.1 11.6 7.9 15.9 43.7 21.5 73.6 
Sao Tome and Principe Women 1.8 0.9 3.0 1.9 1.1 3.1 2.2 0.9 3.9 
Saudi Arabia Men 20.2 15.5 25.4 24.6 18.9 31.6 34.1 18.8 53.2 
Saudi Arabia Women 3.5 2.3 4.9 3.0 1.8 4.5 2.6 0.8 5.2 
Senegal Men 17.4 12.6 21.9 21.2 16.8 25.8 29.0 17.5 43.2 
Senegal Women 1.5 0.8 2.1 0.9 0.5 1.3 0.4 0.2 0.8 
Serbia Men 54.8 41.6 68.3 46.8 37.0 56.6 37.7 22.3 54.9 
Serbia Women 40.4 30.8 51.6 40.5 30.6 49.2 40.8 24.6 59.7 
Seychelles Men 48.2 34.0 64.6 44.7 31.7 59.9 41.4 21.1 66.3 
Seychelles Women 11.1 7.2 15.3 9.3 6.4 13.2 7.2 3.5 11.7 
Sierra Leone Men 39.9 26.0 55.3 52.1 38.8 66.4 77.0 48.6 100.0 
Sierra Leone Women 20.6 11.9 31.6 14.4 9.0 20.8 8.8 3.7 14.6 
Singapore Men 27.5 21.7 33.5 27.8 21.5 33.4 29.0 16.4 43.8 
Singapore Women 5.9 4.5 7.5 5.2 3.9 6.5 4.4 2.2 7.2 
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Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Slovakia Men 46.2 31.1 61.1 40.8 27.7 56.1 35.8 13.4 61.9 
Slovakia Women 21.1 12.8 30.5 18.8 10.4 28.1 16.6 5.0 30.1 
Slovenia Men 30.2 23.2 36.7 24.3 19.2 29.5 18.0 10.6 26.7 
Slovenia Women 22.6 18.2 28.1 19.2 15.4 24.0 15.4 8.7 22.2 
Solomon Islands Men 65.0 44.5 86.2 53.4 37.8 70.9 42.6 16.4 73.5 
Solomon Islands Women 26.9 17.3 37.0 23.0 16.6 31.1 19.5 7.1 34.8 
South Africa Men 34.5 26.9 42.6 34.2 27.5 41.1 34.3 20.8 47.4 
South Africa Women 11.2 8.8 14.0 9.3 7.5 11.3 7.1 4.3 10.1 
Spain Men 45.2 35.3 56.2 35.2 29.3 43.0 24.6 16.8 33.2 
Spain Women 32.3 24.0 40.3 28.7 23.5 35.2 24.8 16.5 34.5 
Sri Lanka Men 31.4 24.9 38.6 29.9 21.1 39.5 29.6 9.4 54.2 
Sri Lanka Women 1.9 1.3 2.6 0.6 0.4 0.9 0.1 0.0 0.2 
Suriname Men 75.5 42.7 100.0 59.5 35.2 100.0 39.3 15.6 72.1 
Suriname Women 17.6 7.3 32.3 12.3 5.7 22.4 7.4 2.5 13.9 
Swaziland Men 15.9 12.1 20.9 17.9 13.2 23.3 22.2 10.3 39.3 
Swaziland Women 3.3 2.0 4.5 2.5 1.5 3.5 1.8 0.7 3.1 
Sweden Men 33.0 25.2 40.6 23.9 19.9 28.2 14.9 10.2 19.5 
Sweden Women 34.7 26.8 42.1 24.5 20.1 28.5 14.6 9.7 18.7 
Switzerland, Liechtenstein Men 34.7 28.6 40.8 29.3 24.5 34.6 23.0 16.3 29.8 
Switzerland, Liechtenstein Women 25.8 20.9 30.0 21.9 17.9 25.5 17.0 12.1 21.8 
Syria Men 50.7 28.4 79.7 70.1 43.3 100.0 88.9 50.3 100.0 
Syria Women 14.0 4.9 25.6 16.5 5.4 32.9 22.9 4.1 55.7 
Tajikistan Women 0.3 0.1 0.7 0.3 0.1 0.5 0.2 0.1 0.5 
Thailand Men 46.3 38.4 54.6 42.9 36.6 49.8 38.2 28.3 47.8 
Thailand Women 3.1 2.6 3.6 2.5 2.1 2.9 1.8 1.3 2.4 
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Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Timor-Leste Men 90.4 65.1 100.0 90.7 74.0 100.0 82.5 51.5 100.0 
Timor-Leste Women 6.5 3.2 11.1 4.3 2.6 6.4 2.5 0.9 4.5 
Togo Men 10.8 5.3 17.3 14.0 8.5 20.5 21.6 10.3 35.5 
Togo Women 3.5 1.3 6.3 2.4 1.1 4.0 1.4 0.5 2.5 
Tonga Men 55.0 40.9 69.5 48.9 38.3 60.9 42.4 23.9 64.0 
Tonga Women 15.4 11.2 20.3 13.5 10.6 17.4 11.5 5.8 18.1 
Trinidad and Tobago Men 44.4 23.4 67.7 40.8 30.2 54.1 38.9 19.3 61.9 
Trinidad and Tobago Women 15.7 8.7 25.2 10.2 7.3 13.1 5.7 2.5 9.1 
Tunisia Men 56.2 41.0 71.4 62.0 42.0 86.4 69.0 30.1 100.0 
Tunisia Women 6.1 3.5 9.0 2.6 1.4 3.9 0.8 0.2 1.6 
Turkey Men 58.6 44.4 71.8 44.9 37.3 53.6 30.8 20.5 42.5 
Turkey Women 19.6 15.4 24.7 14.4 11.6 17.0 9.2 6.1 12.7 
Turkmenistan Men 21.0 10.9 34.7 17.5 11.9 24.5 13.9 8.0 20.8 
Turkmenistan Women 0.9 0.4 1.5 0.8 0.5 1.2 0.6 0.3 1.0 
Tuvalu Men 73.8 52.5 100.0 62.3 35.8 94.5 49.4 22.6 100.0 
Tuvalu Women 29.8 17.3 45.9 25.5 12.4 40.7 21.5 6.0 44.0 
Uganda Men 27.4 18.4 35.9 19.2 13.8 24.9 11.7 6.2 19.2 
Uganda Women 4.8 3.1 6.3 3.3 2.4 4.5 2.0 1.0 3.3 
Ukraine Men 60.3 48.7 72.4 52.3 43.5 62.5 43.1 31.5 57.1 
Ukraine Women 16.1 12.3 19.4 14.6 12.3 17.5 12.6 8.7 17.6 
United Arab Emirates Men 20.2 14.1 27.2 28.6 17.8 40.1 50.2 18.9 95.6 
United Arab Emirates Women 2.3 1.2 3.4 2.7 1.3 4.4 3.8 0.8 8.0 
United Kingdom Men 49.4 37.0 64.5 36.5 26.9 47.1 24.0 14.7 37.0 
United Kingdom Women 46.2 35.6 58.4 33.8 25.1 43.1 21.5 12.8 32.1 
United Republic of Tanzania Men 38.5 23.7 54.8 31.0 22.8 40.7 23.6 12.6 36.5 
United Republic of Tanzania Women 4.9 2.3 7.7 4.1 2.3 6.2 3.3 1.6 5.6 
  133 
Country Sex Prevalence 2000, % Prevalence 2010, % Prevalence 2025, % 
Mean 95% CrI Mean 95% CrI Mean 95% CrI 
United States of America Men 36.3 28.3 45.7 28.6 22.0 35.3 20.2 13.8 28.0 
United States of America Women 29.2 23.0 37.7 22.0 17.7 27.4 14.4 10.0 19.0 
Uruguay Men 48.3 36.0 59.3 32.4 26.4 39.1 18.1 12.1 25.4 
Uruguay Women 37.2 29.1 45.8 23.8 19.1 28.8 12.4 7.9 17.2 
Uzbekistan Men 30.8 21.3 43.4 26.6 17.7 36.8 22.1 8.6 38.7 
Uzbekistan Women 1.6 0.9 2.4 1.4 0.8 2.1 1.2 0.5 2.2 
Vanuatu Men 72.2 39.9 100.0 60.8 34.0 100.0 46.9 15.2 88.7 
Vanuatu Women 24.1 5.3 50.9 20.3 5.6 44.0 16.6 4.0 38.6 
Venezuela Men 51.2 22.7 100.0 39.1 10.9 79.2 26.4 6.2 55.2 
Venezuela Women 33.4 7.9 72.8 23.6 7.6 48.9 14.3 3.2 32.3 
Viet Nam Men 51.2 39.8 65.3 48.5 39.9 57.9 45.9 30.8 65.6 
Viet Nam Women 1.8 1.3 2.4 1.4 1.1 1.7 1.0 0.6 1.5 
Yemen Men 35.6 20.3 52.3 51.6 28.9 81.4 78.4 37.1 100.0 
Yemen Women 14.3 7.4 21.8 16.7 7.7 26.9 22.4 5.5 45.3 
Zambia Men 31.1 23.1 39.6 27.6 19.6 35.7 24.2 10.4 41.0 
Zambia Women 6.1 3.6 8.3 5.1 3.0 7.0 4.0 1.4 7.2 
Zimbabwe Men 33.2 25.3 43.2 32.1 24.5 40.0 31.6 17.2 50.6 
Zimbabwe Women 3.2 1.9 4.4 2.4 1.4 3.5 1.7 0.6 3.0 
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Appendix D: Relative reductions and posterior probabilities 
Country Sex 
Relative reduction 
in prevalence, %, 
2010-2025 
Posterior probability 
Decrease Increase 
Target 
achievement 
Albania Men -9.1 0.72 0.28 0.11 
Albania Women -35.0 0.98 0.02 0.68 
Algeria Men 27.0 0.30 0.70 0.06 
Algeria Women -75.0 1.00 0.00 1.00 
Andorra Men -9.9 0.71 0.29 0.15 
Andorra Women -10.2 0.72 0.28 0.16 
Argentina Men -29.8 0.97 0.03 0.54 
Argentina Women -45.6 1.00 0.00 0.92 
Armenia Men -20.8 0.94 0.06 0.25 
Armenia Women -41.0 1.00 0.00 0.85 
Australia Men -37.5 1.00 0.00 0.81 
Australia Women -42.6 1.00 0.00 0.92 
Austria Men -21.5 0.92 0.08 0.29 
Austria Women -15.7 0.83 0.17 0.20 
Azerbaijan Men -19.6 0.83 0.18 0.35 
Azerbaijan Women -33.8 0.96 0.04 0.63 
Bahamas Men 0.6 0.56 0.44 0.18 
Bahamas Women -41.9 0.97 0.03 0.79 
Bahrain Men 146.1 0.00 1.00 0.00 
Bahrain Women 72.2 0.07 0.93 0.00 
Bangladesh Men -36.5 1.00 0.00 0.72 
Bangladesh Women -87.9 1.00 0.00 1.00 
  135 
Country Sex 
Relative reduction 
in prevalence, %, 
2010-2025 
Posterior probability 
Decrease Increase 
Target 
achievement 
Belgium Men -25.7 0.96 0.04 0.40 
Belgium Women -16.3 0.83 0.17 0.22 
Belize Men -40.5 0.96 0.04 0.72 
Belize Women -45.5 0.99 0.02 0.81 
Benin Men 50.5 0.07 0.93 0.00 
Benin Women -36.0 0.96 0.05 0.69 
Bolivia Men -40.1 0.98 0.03 0.78 
Bolivia Women -35.3 0.97 0.03 0.67 
Bosnia Herzegovina Men -18.1 0.86 0.14 0.24 
Bosnia Herzegovina Women -17.0 0.83 0.17 0.27 
Botswana Men 25.3 0.24 0.77 0.02 
Botswana Women -25.6 0.90 0.10 0.47 
Brazil Men -34.6 0.98 0.02 0.68 
Brazil Women -37.3 0.99 0.02 0.74 
Brunei Darussalam Men -0.3 0.58 0.42 0.19 
Brunei Darussalam Women -39.6 0.95 0.05 0.73 
Bulgaria Men -26.7 0.93 0.07 0.46 
Bulgaria Women -32.4 0.96 0.04 0.60 
Burkina Faso Men 56.3 0.05 0.95 0.00 
Burkina Faso Women -47.3 1.00 0.00 0.88 
Burundi Men -22.1 0.86 0.14 0.41 
Burundi Women -24.3 0.89 0.11 0.42 
Cambodia Men -12.2 0.73 0.27 0.23 
Cambodia Women -64.4 1.00 0.00 1.00 
Cameroon Men 215.8 0.00 1.00 0.00 
Cameroon Women 3.4 0.49 0.51 0.08 
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Country Sex 
Relative reduction 
in prevalence, %, 
2010-2025 
Posterior probability 
Decrease Increase 
Target 
achievement 
Canada Men -39.5 1.00 0.00 0.90 
Canada Women -53.6 1.00 0.00 1.00 
Cape Verde Men 62.0 0.05 0.95 0.00 
Cape Verde Women -38.6 0.97 0.03 0.75 
Chad Men 163.5 0.00 1.00 0.00 
Chad Women 17.4 0.31 0.69 0.04 
Chile Men -18.3 0.87 0.13 0.26 
Chile Women -18.8 0.86 0.14 0.26 
China Men -15.2 0.82 0.18 0.18 
China Women -48.4 1.00 0.00 0.93 
Colombia Men -32.1 0.95 0.05 0.58 
Colombia Women -37.2 0.96 0.04 0.71 
Comoros Men -20.1 0.86 0.14 0.34 
Comoros Women -56.5 1.00 0.00 0.97 
Congo Men 257.5 0.00 1.00 0.00 
Congo Women 13.0 0.35 0.65 0.05 
Cook Islands Men -23.5 0.85 0.15 0.44 
Cook Islands Women -16.1 0.78 0.22 0.32 
Costa Rica Men -32.8 0.91 0.09 0.62 
Costa Rica Women -37.0 0.95 0.05 0.69 
Cote d'Ivoire Men 57.3 0.05 0.95 0.00 
Cote d'Ivoire Women -38.7 0.98 0.02 0.73 
Croatia Men -1.0 0.56 0.44 0.04 
Croatia Women 22.2 0.16 0.84 0.01 
Cuba Men -5.6 0.61 0.39 0.19 
Cuba Women -39.7 0.97 0.03 0.73 
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Country Sex 
Relative reduction 
in prevalence, %, 
2010-2025 
Posterior probability 
Decrease Increase 
Target 
achievement 
Cyprus Men -14.7 0.78 0.22 0.25 
Cyprus Women -15.7 0.79 0.21 0.27 
Czech Republic Men -8.1 0.73 0.27 0.06 
Czech Republic Women -1.1 0.55 0.45 0.03 
Democratic Republic of the Congo Women 20.8 0.27 0.73 0.03 
Denmark Men -55.2 1.00 0.00 0.99 
Denmark Women -52.4 1.00 0.00 0.99 
Djibouti Men -21.0 0.85 0.15 0.36 
Djibouti Women -22.6 0.86 0.15 0.40 
Dominica Men -1.9 0.60 0.40 0.17 
Dominica Women -41.6 0.96 0.04 0.76 
Dominican Republic Men -7.3 0.65 0.35 0.17 
Dominican Republic Women -37.4 0.97 0.03 0.69 
Ecuador Men -32.2 0.95 0.05 0.59 
Ecuador Women -39.6 0.98 0.02 0.76 
Egypt Men 45.7 0.11 0.90 0.01 
Egypt Women -71.6 1.00 0.00 1.00 
El Salvador Men -38.7 0.96 0.04 0.70 
El Salvador Women -43.5 0.97 0.03 0.77 
Eritrea Men -19.6 0.84 0.16 0.34 
Eritrea Women -23.9 0.87 0.13 0.44 
Estonia Men -24.0 0.96 0.04 0.35 
Estonia Women -6.2 0.69 0.31 0.04 
Ethiopia Men -1.7 0.60 0.40 0.10 
Ethiopia Women -17.5 0.82 0.18 0.28 
  
  138 
Country Sex 
Relative reduction 
in prevalence, %, 
2010-2025 
Posterior probability 
Decrease Increase 
Target 
achievement 
Fiji Men -25.2 0.87 0.13 0.47 
Fiji Women -18.0 0.78 0.22 0.37 
Finland Men -30.1 0.99 0.01 0.55 
Finland Women -26.3 0.98 0.02 0.41 
France Men -20.3 0.92 0.08 0.27 
France Women -8.2 0.71 0.29 0.08 
Gabon Men 190.9 0.00 1.00 0.00 
Gabon Women 18.0 0.30 0.70 0.03 
Gambia Men 55.4 0.06 0.94 0.00 
Gambia Women -37.3 0.98 0.03 0.71 
Georgia Men -8.9 0.73 0.27 0.11 
Georgia Women -9.0 0.70 0.30 0.12 
Germany Men -15.4 0.89 0.11 0.10 
Germany Women -4.1 0.64 0.36 0.02 
Ghana Men 42.8 0.10 0.90 0.00 
Ghana Women -39.6 0.98 0.02 0.73 
Greece Men -12.9 0.77 0.23 0.20 
Greece Women -17.9 0.82 0.18 0.32 
Grenada Men -0.6 0.56 0.45 0.18 
Grenada Women -40.5 0.97 0.03 0.76 
Guatemala Men -39.8 0.95 0.05 0.71 
Guatemala Women -46.3 0.98 0.02 0.82 
Guinea Women -36.2 0.96 0.04 0.69 
Guyana Men -31.7 0.94 0.06 0.58 
Guyana Women -39.7 0.98 0.02 0.75 
  
  139 
Country Sex 
Relative reduction 
in prevalence, %, 
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Posterior probability 
Decrease Increase 
Target 
achievement 
Haiti Men 23.0 0.25 0.75 0.02 
Haiti Women -34.6 0.95 0.05 0.64 
Honduras Men -40.8 0.96 0.04 0.76 
Honduras Women -45.5 0.98 0.02 0.84 
Hungary Men -30.3 0.98 0.03 0.55 
Hungary Women -27.6 0.96 0.04 0.48 
Iceland Men -46.5 1.00 0.01 0.88 
Iceland Women -41.0 0.99 0.01 0.80 
India Men -41.2 0.97 0.03 0.78 
India Women -71.3 1.00 0.00 1.00 
Indonesia Men 27.8 0.07 0.93 0.00 
Indonesia Women -40.9 1.00 0.00 0.84 
Iran Men -22.8 0.86 0.14 0.41 
Iran Women -85.3 1.00 0.00 1.00 
Iraq Men 61.0 0.07 0.93 0.00 
Iraq Women 31.7 0.24 0.76 0.03 
Ireland Men -32.6 0.96 0.04 0.62 
Ireland Women -28.9 0.93 0.07 0.54 
Israel Men -1.3 0.57 0.43 0.08 
Israel Women -12.0 0.74 0.26 0.20 
Italy Men -12.5 0.85 0.15 0.06 
Italy Women -1.5 0.57 0.43 0.01 
Jamaica Men 0.0 0.55 0.45 0.11 
Jamaica Women -33.7 0.94 0.06 0.62 
Japan Men -32.6 0.99 0.01 0.63 
Japan Women -27.4 0.97 0.03 0.46 
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in prevalence, %, 
2010-2025 
Posterior probability 
Decrease Increase 
Target 
achievement 
Jordan Men 46.4 0.05 0.95 0.00 
Jordan Women 39.9 0.15 0.86 0.01 
Kazakhstan Men -24.9 0.94 0.07 0.40 
Kazakhstan Women -14.1 0.78 0.22 0.22 
Kenya Men -21.5 0.89 0.11 0.35 
Kenya Women -29.2 0.92 0.08 0.52 
Kiribati Men -24.6 0.85 0.15 0.43 
Kiribati Women -14.2 0.74 0.26 0.28 
Kuwait Men 57.3 0.06 0.94 0.00 
Kuwait Women 32.8 0.24 0.76 0.04 
Kyrgyzstan Men -1.7 0.57 0.43 0.04 
Kyrgyzstan Women -26.4 0.94 0.06 0.46 
Lao People's Dem. Rep. Men -22.8 0.93 0.07 0.35 
Lao People's Dem. Rep. Women -55.3 1.00 0.00 0.99 
Latvia Men -13.0 0.83 0.17 0.10 
Latvia Women -2.2 0.58 0.42 0.04 
Lebanon Men 33.4 0.15 0.85 0.01 
Lebanon Women 32.4 0.20 0.80 0.02 
Lesotho Men 56.3 0.04 0.96 0.00 
Lesotho Women -21.7 0.86 0.14 0.39 
Liberia Men 47.9 0.09 0.91 0.00 
Liberia Women -38.5 0.98 0.02 0.73 
Libya Men 17.2 0.31 0.69 0.08 
Libya Women -75.2 1.00 0.00 1.00 
Lithuania Men -28.1 0.96 0.04 0.49 
Lithuania Women 4.0 0.45 0.55 0.03 
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Posterior probability 
Decrease Increase 
Target 
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Luxembourg Men -22.0 0.91 0.09 0.34 
Luxembourg Women -15.1 0.82 0.18 0.19 
Madagascar Men -12.5 0.74 0.26 0.23 
Madagascar Women -43.0 0.99 0.01 0.83 
Malawi Men -21.6 0.93 0.08 0.29 
Malawi Women -37.0 0.98 0.02 0.71 
Malaysia Men -19.0 0.84 0.16 0.34 
Malaysia Women -53.5 1.00 0.01 0.92 
Maldives Men -18.4 0.77 0.23 0.38 
Maldives Women -73.1 1.00 0.00 1.00 
Mali Men 75.7 0.01 0.99 0.00 
Mali Women -16.1 0.78 0.22 0.28 
Malta Men -22.5 0.90 0.10 0.36 
Malta Women -19.0 0.85 0.16 0.30 
Marshall Islands Men -21.4 0.82 0.18 0.41 
Marshall Islands Women -14.4 0.73 0.27 0.32 
Mauritania Men 76.4 0.02 0.98 0.00 
Mauritania Women -33.0 0.95 0.05 0.62 
Mauritius Men -11.2 0.75 0.25 0.17 
Mauritius Women -30.5 0.96 0.05 0.53 
Mexico Men -44.4 1.00 0.00 0.94 
Mexico Women -48.4 1.00 0.00 0.97 
Mongolia Men -13.3 0.78 0.22 0.19 
Mongolia Women -41.2 0.99 0.01 0.81 
Morocco Men 32.5 0.17 0.83 0.00 
Morocco Women -64.2 1.00 0.00 0.98 
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Posterior probability 
Decrease Increase 
Target 
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Mozambique Men -21.1 0.85 0.15 0.38 
Mozambique Women -22.5 0.87 0.13 0.39 
Myanmar Men -41.0 0.97 0.03 0.77 
Myanmar Women -57.9 1.00 0.00 0.95 
Namibia Men 32.7 0.14 0.86 0.00 
Namibia Women -21.4 0.88 0.12 0.34 
Nauru Men -23.7 0.86 0.14 0.45 
Nauru Women -18.8 0.80 0.20 0.38 
Nepal Men -18.1 0.90 0.10 0.20 
Nepal Women -68.1 1.00 0.00 1.00 
Netherlands Men -29.0 0.99 0.01 0.51 
Netherlands Women -23.0 0.97 0.03 0.27 
New Zealand Men -42.2 1.00 0.00 0.92 
New Zealand Women -46.9 1.00 0.00 0.98 
Nicaragua Women -45.3 0.98 0.02 0.82 
Niger Men 119.8 0.00 1.00 0.00 
Niger Women -39.6 0.99 0.01 0.78 
Nigeria Men 59.7 0.04 0.96 0.00 
Nigeria Women -47.6 0.99 0.01 0.89 
Niue Men -29.6 0.92 0.08 0.54 
Niue Women -22.4 0.84 0.16 0.43 
Norway Men -47.9 1.00 0.00 0.98 
Norway Women -46.8 1.00 0.00 0.98 
Oman Men 72.9 0.03 0.97 0.00 
Oman Women 27.1 0.28 0.72 0.04 
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Pakistan Men 18.2 0.28 0.72 0.02 
Pakistan Women -62.4 1.00 0.00 0.99 
Palau Men -21.8 0.83 0.17 0.40 
Palau Women -11.8 0.72 0.28 0.29 
Palestine Men 72.8 0.05 0.95 0.00 
Palestine Women 32.5 0.23 0.77 0.03 
Panama Men -54.8 1.00 0.00 0.95 
Panama Women -47.2 0.99 0.01 0.86 
Papua New Guinea Men -24.5 0.87 0.13 0.45 
Papua New Guinea Women -17.0 0.79 0.21 0.34 
Paraguay Men -38.5 0.99 0.01 0.76 
Paraguay Women -43.2 1.00 0.00 0.84 
Peru Women -37.4 0.99 0.02 0.71 
Philippines Men -25.9 0.95 0.05 0.41 
Philippines Women -32.2 0.98 0.02 0.61 
Poland Men -27.4 0.95 0.05 0.47 
Poland Women -35.8 0.99 0.02 0.70 
Portugal Men -13.7 0.80 0.20 0.17 
Portugal Women -9.8 0.71 0.29 0.20 
Qatar Men 94.0 0.02 0.98 0.00 
Qatar Women 19.7 0.33 0.67 0.05 
Republic of Korea Men -18.5 0.83 0.17 0.28 
Republic of Korea Women -24.7 0.90 0.10 0.44 
Republic of Moldova Men 13.0 0.26 0.74 0.00 
Republic of Moldova Women 1.2 0.51 0.49 0.04 
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Romania Men -29.1 0.96 0.04 0.52 
Romania Women -15.6 0.81 0.19 0.20 
Russian Federation Men -14.4 0.83 0.17 0.17 
Russian Federation Women 5.9 0.42 0.58 0.03 
Rwanda Men -19.7 0.83 0.17 0.35 
Rwanda Women -14.0 0.78 0.23 0.22 
Saint Kitts and Nevis Men -0.2 0.57 0.43 0.16 
Saint Kitts and Nevis Women -42.8 0.98 0.02 0.79 
Saint Vincent and the Grenadines Men -1.1 0.58 0.42 0.17 
Saint Vincent and the Grenadines Women -40.7 0.96 0.04 0.75 
Samoa Men -29.5 0.93 0.07 0.54 
Samoa Women -25.1 0.88 0.12 0.45 
Sao Tome and Principe Men 277.5 0.00 1.00 0.00 
Sao Tome and Principe Women 14.5 0.35 0.65 0.04 
Saudi Arabia Men 37.9 0.08 0.92 0.00 
Saudi Arabia Women -17.2 0.76 0.24 0.34 
Senegal Men 36.8 0.08 0.92 0.00 
Senegal Women -50.5 1.00 0.00 0.93 
Serbia Men -19.5 0.90 0.10 0.25 
Serbia Women 0.8 0.52 0.48 0.04 
Seychelles Men -8.0 0.70 0.30 0.11 
Seychelles Women -23.0 0.91 0.09 0.35 
Sierra Leone Men 48.8 0.05 0.95 0.00 
Sierra Leone Women -39.2 0.98 0.02 0.73 
Singapore Men 3.8 0.46 0.55 0.03 
Singapore Women -16.3 0.81 0.19 0.25 
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Slovakia Men -13.6 0.74 0.26 0.25 
Slovakia Women -13.8 0.77 0.24 0.25 
Slovenia Men -26.1 0.95 0.05 0.43 
Slovenia Women -20.2 0.91 0.10 0.27 
Solomon Islands Men -21.4 0.84 0.17 0.41 
Solomon Islands Women -16.3 0.77 0.23 0.32 
South Africa Men 0.5 0.51 0.49 0.03 
South Africa Women -23.5 0.93 0.07 0.35 
Spain Men -29.8 0.99 0.01 0.53 
Spain Women -13.6 0.82 0.18 0.13 
Sri Lanka Men -3.9 0.61 0.39 0.17 
Sri Lanka Women -81.8 1.00 0.00 1.00 
Suriname Men -33.3 0.94 0.05 0.62 
Suriname Women -38.5 0.99 0.02 0.75 
Swaziland Men 22.8 0.26 0.74 0.02 
Swaziland Women -29.9 0.93 0.08 0.54 
Sweden Men -37.3 1.00 0.00 0.77 
Sweden Women -40.1 1.00 0.00 0.85 
Switzerland Men -21.3 0.97 0.04 0.23 
Switzerland Women -21.9 0.97 0.03 0.23 
Syria Men 29.9 0.05 0.93 0.00 
Syria Women 32.2 0.24 0.76 0.03 
Tajikistan Women -17.1 0.79 0.21 0.31 
Thailand Men -10.7 0.82 0.18 0.04 
Thailand Women -25.7 0.98 0.02 0.36 
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Timor-Leste Men -8.7 0.59 0.38 0.15 
Timor-Leste Women -41.2 0.96 0.04 0.75 
Togo Men 56.2 0.05 0.95 0.00 
Togo Women -39.5 0.97 0.03 0.77 
Tonga Men -13.6 0.79 0.21 0.20 
Tonga Women -15.2 0.79 0.21 0.25 
Trinidad and Tobago Men -3.4 0.59 0.41 0.19 
Trinidad and Tobago Women -43.3 0.97 0.03 0.81 
Tunisia Men 9.3 0.36 0.64 0.09 
Tunisia Women -70.8 1.00 0.00 1.00 
Turkey Men -31.2 0.98 0.02 0.57 
Turkey Women -36.0 1.00 0.01 0.72 
Turkmenistan Men -18.5 0.82 0.18 0.34 
Turkmenistan Women -16.4 0.79 0.21 0.29 
Tuvalu Men -22.8 0.84 0.16 0.41 
Tuvalu Women -18.6 0.80 0.20 0.38 
Uganda Men -39.1 0.99 0.02 0.76 
Uganda Women -40.0 0.99 0.01 0.79 
Ukraine Men -17.3 0.90 0.10 0.15 
Ukraine Women -13.6 0.83 0.17 0.11 
United Arab Emirates Men 71.5 0.05 0.95 0.00 
United Arab Emirates Women 34.6 0.21 0.79 0.02 
United Kingdom Men -34.6 0.99 0.01 0.70 
United Kingdom Women -36.6 1.00 0.01 0.74 
United Republic of Tanzania Men -23.3 0.88 0.12 0.42 
United Republic of Tanzania Women -18.5 0.82 0.18 0.32 
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United States of America Men -29.1 0.99 0.01 0.50 
United States of America Women -34.4 1.00 0.00 0.70 
Uruguay Men -44.1 1.00 0.00 0.92 
Uruguay Women -47.7 1.00 0.00 0.96 
Uzbekistan Men -18.0 0.82 0.18 0.30 
Uzbekistan Women -15.8 0.77 0.23 0.29 
Vanuatu Men -23.2 0.84 0.15 0.42 
Vanuatu Women -18.9 0.81 0.19 0.35 
Venezuela Men -32.6 0.95 0.05 0.61 
Venezuela Women -39.2 0.97 0.03 0.76 
Viet Nam Men -5.2 0.66 0.34 0.06 
Viet Nam Women -29.5 0.95 0.05 0.54 
Yemen Men 53.5 0.06 0.94 0.00 
Yemen Women 30.2 0.24 0.77 0.04 
Zambia Men -13.8 0.75 0.25 0.26 
Zambia Women -21.8 0.87 0.14 0.38 
Zimbabwe Men -1.8 0.58 0.43 0.08 
Zimbabwe Women -30.9 0.95 0.05 0.57 
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Appendix E: Country groupings sensitivity analyses 
Measure Grouping basis Within-group 
variability 
Summary statistics 
Mean SD Min Max 
Men 
Coverage Tobacco control only Low 0.992 0.015 0.938 1.000 
Moderate 0.993 0.016 0.929 1.000 
Geography and  
tobacco epidemiology 
Low 0.993 0.015 0.938 1.000 
Moderate 0.993 0.016 0.929 1.000 
RMSE Tobacco control only Low 0.073 0.032 0.022 0.199 
Moderate 0.070 0.031 0.020 0.194 
Geography and  
tobacco epidemiology 
Low 0.071 0.033 0.022 0.205 
Moderate 0.069 0.031 0.021 0.195 
Women 
Coverage Tobacco control only Low 0.982 0.027 0.865 1.000 
Moderate 0.984 0.024 0.900 1.000 
Geography and  
tobacco epidemiology 
Low 0.982 0.027 0.885 1.000 
Moderate 0.984 0.025 0.900 1.000 
RMSE Tobacco control only Low 0.035 0.027 0.001 0.133 
Moderate 0.034 0.027 0.001 0.132 
Geography and  
tobacco epidemiology 
Low 0.035 0.027 0.001 0.131 
Moderate 0.034 0.026 0.001 0.130 
 
